Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
Gilead Clinical 
Program Manager: 
Gilead Medical 
Monitor: 
Protocol Version/Date: (r'J GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study 
Evaluating the Safety, Tolerability, and Efficacy ofGS-9674 in 
Subjects with Primruy Sclerosing Cholangitis Without Cinhosis 
Gilead Sciences, Inc. 
333 Lakeside D1i.ve 
Foster City, CA 94404 
U.S.A. 
131031 
2016-00244 2-23 
Not Available 
Pli.mruy Sclerosing Cholangitis (PSC) 
GS-US-428-4025 
Name: 
Telephone: 
Email: 
Name: 
Telephone: 
Fax: 
Email: 
01i.ginal: PPD 
1-'1-'U 
1-'1-'U 
~~gphen Djedjos, M.D. 
rl-'u 
29 June 2016 
CONFIDENTI ALITY STATEMENT 
The infonnation contained in this document, prui:iculru·ly unpublished data, is the property or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, yom staff, and an applicable Institutional 
Review Boru·d or Independent Ethics Committee. The inf01mation is only to be used by you in 
connection with authorized clinical studies of the investigational drug described in the protocol. 
You will not disclose any of the inf01mation to others without w1i.tten authorization from 
Gilead Sciences, Inc., except to the extent necessruy to obtain infonned consent from those 
persons to whom the dmg may be administered. 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page2 29 June 2016TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ................................................................
........................................................................ 5
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 14
1.INTRODUCTION .............................................................................................................................................. 18
1.1.Background ............................................................................................................................................ 18
1.2.GS-9674................................................................................................................................................. 19
1.2.1. General Information ............................................................................................................. 19
1.2.2. Nonclinical Toxicology ........................................................................................................ 19
1.2.3. Nonclinical Pharmacology ................................................................................................... 20
1.2.4. Nonclinical Pharmacokinetics .............................................................................................. 21
1.2.5. Clinical Trials of GS -9674................................................................................................... 22
1.3.Rationale for this Study .......................................................................................................................... 26
1.3.1. Risk/Benefit Assessment for the Study ................................................................................ 27
1.4.Compliance............................................................................................................................................ 27
2.OBJECTIVES ................................................................................................
..................................................... 28
3.STUDY DESIGN ................................................................................................................................................ 29
3.1.Study Design .......................................................................................................................................... 29
3.2.Treatment Plan and Regimen ................................................................................................................. 30
3.3.Biomarker Testing .................................................................................................................................. 30
3.3.1. Biomarker Samples to Address the Study Objectives: ......................................................... 30
3.3.2. Biomarker Samples for Optional Future Research ............................................................... 31
3.3.3. Biomarker Samples for Optional Genomic Research ........................................................... 31
4.SUBJECT POPULATION .................................................................................................................................. 32
4.1.Number of Subjects and Subject Selection ............................................................................................ 32
4.2.Inclusion Criteria .................................................................................................................................... 32
4.3.Exclusion Criteria ................................................................................................................................... 33
5.INVESTIGATIONAL MEDI CINAL PRODUCTS........................................................................................... 36
5.1.Randomization, Blinding and Treatment Codes .................................................................................... 36
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 36
5.2.Description and Handling of GS -9674 and PTM GS -9674.................................................................... 36
5.2.1. Formulation.......................................................................................................................... 36
5.2.2. Packaging and Labeling ....................................................................................................... 37
5.2.3. Storage and Handling ........................................................................................................... 37
5.3.Dosage and Administration of GS -9674/PTM GS -9674........................................................................ 37
5.4.Prior and Concomitant Medications ...............................................................
........................................ 38
5.5.Prohibited Medications .......................................................................................................................... 38
5.6.Accountability for GS -9674/ PTM GS -9674......................................................................................... 40
5.6.1 Investigational Medicinal Product Return or Disposal ........................................................ 40
6.STUDY PROCEDURES .................................................................................................................................... 41
6.1.Subject Randomization and Treatment Assignment .............................................................................. 41
6.2.Pretreatment Assessments -Screening Visit ............................................................................................ 41
6.3.Blinded Study Phase: Baseline/Day 1 Randomization and Assessments ............................................... 42
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page3 29 June 20166.4.Treatment Assessments (Blinded Study Phase) ..................................................................................... 44
6.4.1. Weeks 1, 2, 4 and 8 (± 3 days) ............................................................................................. 44
6.4.2. Week 12 (± 3 days) .............................................................................................................. 45
6.5.Blinded Study Phase follow -up Visit (±5 days) ..................................................................................... 47
6.6.Open Label Extension (OLE) Phase (± 5 days) ..................................................................................... 48
6.7.Unscheduled Visits ................................................................................................................................. 49
6.8.OLE follow -up Visit (±5 days) .............................................................................................................. 50
6.9.Assessments for Premature Discontinuation from Study ....................................................................... 50
6.10.Criteria for Discontinuation of Study Treatment .................................................................................... 51
6.11.PK and PD Substudy Visits .................................................................................................................... 51
6.12.Procedures and Specifications ................................................................................................................ 51
6.12.1. Clinical Laboratory Analytes ............................................................................................... 51
6.12.2. Medical History .................................................................................................................... 53
6.12.3. Physical Examination ........................................................................................................... 53
6.12.4. Quality of Life (QoL) Measures and Pruritus Assessments ................................................. 53
6.12.5. Electrocardiogram ................................................................................................................ 54
6.12.6. FibroScan®................................................................
........................................................... 54
6.13.End of Study ........................................................................................................................................... 54
6.13.1. Sample Storage ..................................................................................................................... 55
7.ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 56
7.1.Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 56
7.1.1. Adverse Events ................................
..................................................................................... 56
7.1.2. Serious Adverse Events ........................................................................................................ 56
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 57
7.2.Assessment of Adverse Events and Serious Adverse Events ................................................................. 57
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 57
7.2.2. Assessment of Severity ........................................................................................................ 58
7.3.Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead ...............................................................
........................................................ 58
7.4.Gilead Reporting Requirements ............................................................................................................. 60
7.5.Toxicity Management ............................................................................................................................ 60
7.5.1. PSC Specific Study Stopping Rule:..................................................................................... 60
7.5.2. Observation for Drug Induced Liver Injury (DILI): ............................................................. 60
7.6.Special Situations Reports ...............................................................
....................................................... 63
7.6.1. Definitions of Special Situations .......................................................................................... 63
7.6.2. Instructions for Reporting Special Situations ....................................................................... 64
8.STATISTICAL CONSIDER ATIONS................................................................................................................ 66
8.1.Analysis Objectives and Endpoints ........................................................................................................ 66
8.1.1. Analysis Objectives .............................................................................................................. 66
8.1.2. Primary Endpoint ................................................................................................................. 66
8.1.3. Exploratory Endpoints .......................................................................................................... 67
8.2.Analysis Conventions ............................................................................................................................. 67
8.2.1. Analysis Sets ........................................................................................................................ 67
8.2.2. Analysis by Study Phase ...................................................................................................... 69
8.3.Data Handling Conventions ................................................................................................................... 69
8.4.Demographic Data and Baseline Characteristics ................................................................................... 69
8.5.Efficacy Analysis ................................................................................................................................... 69
8.6.Exploratory Analyses ............................................................................................................................. 70
8.7.Safety Analysis ....................................................................................................................................... 70
8.7.1. Extent of Exposure ............................................................................................................... 70
8.7.2. Adverse Events ..................................................................................................................... 70
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page4 29 June 20168.7.3. Laboratory Evaluations ........................................................................................................ 71
8.7.4. Other Safety Evaluations ...................................................................................................... 71
8.8.Pharmacokinetic Analysis ...................................................................................................................... 71
8.9.Pharmacodynamics Analysis .................................................................................................................. 71
8.10.Biomarker Analysis ................................................................................................................................ 71
8.11.Sample Size..............................................................................................................................
..............72
8.12.Data Monitoring Committee .................................................................................................................. 72
9.RESPONSIBILITIES ................................................................
.......................................................................... 73
9.1.Investigator Responsibilities .................................................................................................................. 73
9.1.1. Good Clinical Practice .......................................................................................................... 73
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval ........................................................................................................... 73
9.1.3. Informed Consent ................................................................................................................. 73
9.1.4. Confidentiality ...................................................................................................................... 74
9.1.5. Study Files and Retention o f Records .................................................................................. 74
9.1.6. Case Report Forms ...............................................................
................................................ 75
9.1.7. Investigational Medicinal Product Accountability and Return ............................................. 76
9.1.8. Inspections ............................................................................................................................ 76
9.1.9. Protocol Compliance ............................................................................................................ 76
9.2.Sponsor Responsibilities ........................................................................................................................ 77
9.2.1. Protocol Modifications ......................................................................................................... 77
9.2.2. Study Report and Publications ............................................................................................. 77
9.3.Joint Investigator/Sponsor Responsibilities ........................................................................................... 77
9.3.1. Payment Reporting ............................................................................................................... 77
9.3.2. Access to Information for Monitoring .................................................................................. 78
9.3.3. Access to Information for Auditing or Inspections .............................................................. 78
9.3.4. Study Discontinuation .......................................................................................................... 78
10.REFERENCES ................................................................................................................................................... 79
11.APPENDICES .................................................................................................................................................... 81
Appendix 1.Investigator Signature Page .................................................................................................... 82
Appendix 2.Study Procedures Table for GS-US-428-4025....................................................................... 83
Appendix 3.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 87
Appendix 4.Pregnancy Precautions, Definition for Female of Childbearing Po
tential, and 
Contraceptive Requirements ................................................................................................... 88
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page5 29 June 2016LIST OF IN -TEXT TABLES
Table1-1. Exposure Margins for GS -9674 Based on Observed GS -9674 Exposure After 
Administration of 100 mg GS-9674 QD Under Fed Conditions at Steady -State in 
Cohort 5 Compared to Exposures Observed at NOAEL Doses in Mouse and 
Cynomolgus Monkey ............................................................................................................. 20
Table1-2. Preliminary Safety Summary of Subjects Following Single -and Multiple -Dose 
Administration of GS -9674 Under Fasting or Fed Conditions in Healthy Volunteers 
(GS-US-402-
1851)................................................................................................................. 23
Table1
-3. Preliminary Plasma Pharmacokinetic Parameters of GS -9674 Follow ing Single -and 
Multiple- Dose Administration of GS -9674 Under Fasting or Fed Conditions in 
Healthy Volunteers (GS -US-402-1851)................................................................................. 25
Table1-4. Preliminary Pharmacodynamic Parameters (FGF19 and C4) Follow ing Multiple -
Dose Administration of Placebo, or GS -9674 Under Fasting or Fed Conditions in 
Healthy Volunteers (GS -US-402-1851)................................................................................. 26
Table5-1. List of Prohibited Medications ............................................................................................... 39
LIST OF IN -TEXT FIGURES
Figure 3-1.Overall Study Design ............................................................................................................. 29
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page6 29 June 2016PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 , U.S.A.
Study Title: A Phase 2, Randomized, Double- Blind, Placebo Controlled Study  
Evaluating the Safet y, Tolerability, and Efficacy of GS-9674 in 
Subjects with Primary  Sclerosing Cholangitis Without Cirrhosis
IND Number:
EudraCT Number :
Clinical Trials.gov 
Identifier:131031
2016-002442-23
Not Available
Study Centers 
Planned:Approximately  30 centers in North America and Europe
Objectives: The primary  objective of this study  is to evaluate the safet y and 
tolerability  of GS-9674 in subjects with primary  sclerosing 
cholangitis (PSC)
The exploratory  objectives of this study  are listed in Section2. 
Study Design: This is a Phase 2 randomized, double -blind, placebo controlled study  
evaluating the safet y, tolerability, and efficacy of GS-9674 in subjects 
with PSC without cirrhosis.
The study  will consist of 2 phases, a Blinded Study Phase and an 
Open Label Extension (OLE)Phase. 
Blinded Study  Phase: Includes a 4- week screening period, 12 weeks 
of blinded treatment, and a Blinded Study  Phase follow-up visit, 4 
weeks after completion of blinded treatment. 
Subjects completing the Blinded Study  Phase without permanentl y 
discontinuing study  drug will be eligible to participate in the OLE 
Phase of the stud y.
OLE Phase:  Includes a 96-week OLE and an OLEPhase follow-
up 
visit 4weeks after comp letion of open label treatment.
Participation in the Blinded Study  Phase can last up to 20 weeks and 
the OLE Phase can last up to 100 weeks, thus total study  duration can 
be up 120 weeks.
Subjects meeting the study ’s entry criteria will be randomly  assigned 
in a 2:2:1 ratio to 1 of 3 treatment groups during the Blinded Study  
Phase as shown in the figure below:
GS-9674
Protocol GS-US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page7 29 June 2016Randomization will be stratified b y the presence or absence of 
ursodeoxycholic acid (UDCA) use. 
Number of Subjects 
Planned:Approximately  50Subjects
Target Population: Males and non -pregnant, females between 18 -70 years of age with 
PSC without cirrhosis
Duration of 
Treatment:Total study  duration of up to 120 weeks with up to 20 Weeksfor the 
Blinded Study  Phase and up to 100 weeks for the OL E Phase.
Diagnosis and Main 
Eligibility  Criteria:Key inclusion and exclusion criteria are as follows:
Inclusion Criteria
Diagnosis of PSC based on cholangiogram (magnetic 
resonance cholangiopancreatograph y [MRCP], endoscopic 
retrograde cholangiopancreatograph y [ERCP], or 
percutaneous transhepatic cholangiogram [PTC]) within the 
previous 12 months;
Serum AL P >1.67 x ULN;
For subjects on ursodeoxycholic acid (UDCA), the dose of 
UDCA must have been stable for at least 6months prior to 
screening through the end of treatment . For subjects not on 
UDCA, no UDCA use for at least before screening through 
the end of treatment ;
For subjects being administered biologic treatments ( eg, anti-
tumor necrosis factor [TNF] or anti-integrin monoclonal 
antibodies), immunosuppressants orsystemic corticosteroids,  
the dose must have been stable at least 3 months prior to

GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page8 29 June 2016screeningand anticipated to remain stable throughout the trial;
Screening FibroSURE/ FibroTest®<0.75.
Exclusion Criteria
ALT > 10xUL N;
Total bilirubin > 2x UL N;
INR >1.2 unless on anticoagulant therap y;
Serum albumin < 3.0 g/dL;
Cirrhosis of the liver as defined by  any of the following:
a)Historical liver biopsy  demonstrating stage 4 fibrosis 
according to the Ludwig classification (or equivalent); 
b) History of decompensated liver disease, including 
ascites, hepatic encephalopathy  or variceal bleeding ;
c)Liver stiffness >14.4 kPa by  FibroScan®
Small-duct PSC (histologic evidence of PSC with normal bile 
ducts on cholangiography);
Other causes of liver disease including secondary sclerosing 
cholangitis and viral, metabolic, alcoholic, and other 
autoimmune condition s;
Ascending cholangitis within 60 days of screening;
Presence of a percutaneous drain or bile duct stent;
Use of fib rates or obeticholic acid within 3 months prior to
screening and through the end of treatment;
Current, active inflammatory  bowel disease (IBD) defined as 
a partial May o score of > 2.
Please refer to section 4.2and 4.3of the protocol for detailed 
inclusion and exclusion criteria. 
Study Procedures/
Frequency :Blinded Study Phase
After signing the informed consent form, subjects will complete a 
screening visit which will include the following assessments: 
complete medical history, complete physical examination (PE), vital 
signs, cirrhosis assessment s, laboratory  assessments (blood 
chemistry , hematology , coagulation panel, andbiomarkers) , 
calculation of partial May o score for subjects with IBD, serum 
pregnancy  test (forfemales of childbearing potential), urine drug test
andreview of adverse events (AEs) related to screening proced ures 
and concomitant medications (CMs). 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
CONFIDENTIAL Final 
Original 
After the screening period, visits will occur at Baseline/Day 1 and at 
Weeks 1, 2, 4, 8, and 12. At minimum, vital signs, symptom-driven 
PE, safety laboratory tests (blood chemistry, hematology, and 
coagulation panel), calculation of partial Mayo score for subjects with 
IBD and review of adverse events and concomitant medications will 
be done at every visit. 
PPD 
Eligible subjects will be randomized to one of three treatment groups 
of the Blinded Study Phase. Prior to initial dosing, required 
Baseline/Day 1 assessments will be performed and will include, 
symptom-driven PE, vital signs, laboratory assessments, pregnancy 
tests (for females of child-bearing potential), urine, blood, and stool 
collection for biomarker assessments, pruritus assessments and 
Quality of Life (QoL) questionnaires, standard 12-lead ECG, 
FibroScan®, review of AEs and CMs. 
PPD 
While on study, subjects will undergo the following procedures and 
laboratory assessments: 
• Symptom-directed PE and vital signs at Baseline/Day 1 and at 
Weeks 1, 2, 4, 8 and 12 
• Height at Baseline/Day 1 and weight at all visits 
• FibroScan® (if available) at Baseline/Day 1 and Week 12 
• 12-lead ECG at Baseline/Day 1 and Week 12 
• C-peptide, insulin and hemoglobin Ale (HbAlc) at Baseline/Day 
1 and Week 12 
• PK and PD sampling at Baseline/Day 1 (PD only) and at Weeks 
1, 2, 4, 8 and 12 
• Blood for Biomarker assessments at Baseline/Day 1 and at Weeks 
1, 4, and 12 
• Urine Biomarker collection at Baseline/Day 1 and at Weeks 1, 4, 
and 12 
Page 9 29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page10 29 June 2016Urine pregnancy  testing (females of childbearing potential only ) 
at Baseline/ Day 1 and Weeks 1, 4 , 8 and 12 
Stool collection at Baseline/ Day 1 and Week 12
Hematology , blood chemistry ,  coagulation panel (PT, PTT, I NR) 
and fasting lipid profile at Baseline/Day 1 and Weeks 1, 2, 4, 8, 
and 12 
QoL Questionnaires: PBC-40, 
SF-36, and PSC Patient -Reported 
Outcome (PRO) at Baseline/Day 1 and Week 12 
Pruritus Asse ssments: Pruritus Visual Analog Scale ( VAS)and 
5D
-Itchquestionnaire at Baseline/Day 1 and at Weeks 1, 2, 4, 8, 
and 12
Partial May o score calculation at Baseline/Day 1 andatWeeks 1, 
2, 4, 8, and 12 for subjects with IBD
At the Blinded Study  Phase follow
up visit, subjects will have a 
symptom-driven PE, vital signs, laboratory  assessments, urine 
pregnancy  tests (for females of childbearing potential), urine, stool 
and blood collection for biomarker assessments, QoL  and pruritus 
questionnaires (PBC -40,SF-
36, PSC-PRO, Pruritus VAS and 
5D-
Itch), weight, review of AEs, and review of CMs and serum will 
be drawn for hematology, blood chemistry , and a coagulation panel.
Subjects will be unblinded to their Blinded Study  Phasetreatment 
assignment after the primary  analysis has been completed, 
approximately  6 weeks after all subjects have completed the Blinded 
Study Phase.
During the Blinded S tudy Phase early termination (ET)visit,subjects 
who prematurely  discontinue participation will complete Week 12 
assessments and will also complete the Blinded Study  follow-
up visit 
4 weeks after their last dose if possible .  
Open-Label Extension (OLE) Phase
Subjects who do not permanently  discontinue study drug and 
complete the Blinded Study  Phase follow-upvisit will be eligible to 
enter into the OLEPhase of the study for 96 weeks. Subjects will 
begin open
-label treatment with GS-9674 (100 mg po once dail y).  
The dose of GS -9674 may  be reduced from 100 mg to 30mg (or 
subsequently  increased back to 100 mg) at the PI’s discretion with the 
approval of the Medical Monitor ( MM), ifrequireddue to 
tolerability . In the OLE Phase, subjects will have in- clinic study  
assessments at OL EBaseline/Day  1,OLE Week 4, OLEWeek 12, 
and every  12 weeks thereafter for s ymptom-driven PE, vital signs, 
laboratory  assessments, urine pregnancy  tests (for females of 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
Test Product: 
Reference Product: 
Dose and Mode of 
Administration: 
CONFIDENTIAL Final 
Original 
childbearing potential), urine, stool and blood collection for 
biomarker assessments , calculation of partial Mayo score (subjects 
with IBD), QoL and pruritus questionnaires (PBC-40, SF-36, PSC 
PRO, Pruritus VAS and 5D-Itch), weight, and review of AEs and 
CMs. 
Subjects in the OLE Phase will the complete treatment Week 96 visit 
and then return for their final visit, the OLE follow up visit 4 weeks 
following the last dose of study drug. Subjects who prematurely 
discontinue participation in the OLE Phase will complete the Week 
96 assessments and will also complete the follow-up visit 4 weeks 
after their last dose if possible. 
At the OLE follow up visit, subjects will have a symptom-driven PE, 
measurement ofvital signs, review of AEs, CMs, pruritus and 
assessment and serum will be drawn for hematology, blood 
chemistry, lipids, and a coagulation panel. A urine pregnancy test will 
be performed for females of childbearing potential only. 
GS-9674 is supplied as 30 mg and 100 mg strength 
tablets. The tablets contain GS-9674-02 
mg are orange 
tablets and GS-9674 100 mg tablets are capsule-shaped , plain-faced, 
film-coated orange tablets. 
Placebo-to-match (PTM) GS-9674 tablets are identical in size, shape, 
color and appearance to their corresponding strengths of active 
GS-9674 tablets. PTM GS-9674 tablets contain the follow· 
• Treatment Group A: GS-9674 30 mg (1 x 30 mg tablet)+ PTM 
GS-9674 100 mg (1 x PTM 100 mg tablet) administered orally 
once daily with food. 
• Treatment Group B: GS-9674 100 mg (1 x 100 mg tablet)+ 
PTM GS-9674 30 mg (1 x PTM 30 mg tablet) administered orally 
once daily with food. 
Treatment Group C: PTM GS-9674 30 mg (1 x PTM 30 mg 
tablet)+ PTM GS-9674 100 mg (1 x PTM 100 mg tablet) 
administered orally once daily with food. 
Page 11 29 June 2016 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
Criteria for 
Evaluation: 
Safety: Final 
Original 
The primary endpoint is the safety of GS-9674 in subjects with PSC 
without cirrhosis. 
Safety will be assessed during the study through the reporting of AEs, 
and by clinical laboratory tests and vital sign assessments at various 
time points during the study. Concomitant medication usage will also 
be assessed throughout the study. 
An independent , external Data Monitoring Committee (DMC) that 
consists oftwo hepatologists and a PhD statistician will convene once 
20 subjects have been randomized and every 3 to 4 months thereafter 
to monitor the study for safety events in Blinded Study Phase and 
every 6 month in the OLE Phase. The DMC will meet on an ad hoc 
basis ifthere are at least 3 similar Grade 2:: 3 serious, treatment related 
Common Terminology Criteria for Adverse Events (CTCAE) 
observed in the study. In the event of two similar treatment-related 
Grade 4 CTCAE events or one treatment-related Grade 5 CTCAE, 
the DMC will review the data and advise the sponsor regarding 
stopping or continuing the study. 
Efficacy: Efficacy will be assessed through a number of exploratory endpoints. 
These exploratory endpoints are described in Section 8.1.3. 
Pharmacokinetic and A single predose PK and PD blood sample will be collected at each 
Pharmacodynamic: on-treatment visit for all subjects. Plasma concentrations of GS-9674, 
GS-716070 (metabolite ofGS-9674), and other metabolites as 
appropriate, will be determined for PK analyses as applicable. Plasma 
or serum concentrations of FGF 19, C4, and bile acids will be 
determined as applicable for PD analyses. 
Statistical Methods: 
Safety Analysis: 
Efficacy Analysis: 
CONFIDENTIAL All safety data collected will be listed and be summarized, as 
appropriate, by treatment group. 
The biological and histological activity of study drugs will be 
evaluated using histologic endpoints and biomarker variables. 
PPD 
PPD 
Page 12 29 June 2016 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
Exploratory 
Analysis: 
Sample Size: PPD Final 
Original 
Due to the exploratory nature of this study, no formal power 
calculations were used to determine sample size. The number of 
subjects was chosen based on clinical experience with other similar 
proof of concept studies. 
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents. 
CONFIDENTIAL Page 13 29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page14 29 June 2016GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
AE adverse event
ALT alanine aminotransferase
ALP alkaline phosphatase
AMA anti-mitochondrial antibodies
Apo B apolipoprotein B
aPTT activated partial thromboplastine time
AST aspartate aminotransferase
ATP Adenosine triphosphate
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration 
versus time curve
-hCG beta human chorionic gonadotropin
BAP Biomarker Analysis Plan
BCRP breast cancer resistance protein
BUN blood urea nitrogen
BW body weight
C4 7-alpha-hydroxy-4-cholesten -3-one
CFR code of federal regulations
CrCL creatinine clearance
Clast last observed quantifiable plasma/serum concentration of the drug
Cmax maximum observed plasma/serum concentration of drug
CMs concomitant medications
CNS central nervous system
CRO contract (or clinical) research organization 
CTCAE Common Terminology Criteria for Adverse Events
CSR clinical study report
CYP3A cytochrome P4503A
CV cardiovascular
DILI drug induced liver injury
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
DSPH Drug Safety and Public Health
EC50 Concentration of drug that gives half -maximum response
ECG electrocardiogram
ET early terminated
eCRF electronic case report form
EDC electronic data capture
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page15 29 June 2016e.g. example
ELF™Test enhanced liver fibrosis test
ERCP endoscopic retrograde cholangiopancreatography
EU European Union
FAS Full analysis set
FDA (United States) Food and Drug Administration
FSH Follicle-stimulating hormone
FGF Fibroblast grow th factor
FXR Farnesoid X Receptor
GCP good clinical practice
GCSF granulocyte colony stimulating factor
GGT gamma glutamyl transferase
GSI Gilead Sciences, Inc.
HbA1c Hemoglobin A1c
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
Hct Hematocrit
HDPE High-density polyethylene
HCV Hepatitis c virus
Hg Hemoglobin
HIV Human immunodeficiency virus
HLT high-level term
HLGT high-level group term
HMG-CoA 3-hydroxy-3-methylglutaryl -coenzyme A
HOMA-IR homeostatic assessment of insulin resistance
IB investigator’s brochure
IBD inflammatory bow el disease
ICF Informed Consent Form
ICH International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC independent ethics committee
IMP Investigational Medicinal Product
IND Investigational New Drug (Application)
INR international normalized ratio
IRB institutional review board
IUD intrauterine device
IWRS interactive web response system
kg Kilogram
LDH lactate dehydrogenase
LLT lower-level term
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page16 29 June 2016MedDRA Medical Dictionary for Regulatory Activities
g Microgram
mg Milligram
min Minute
mL Milliliter
mm Millimeter
mm Hg millimeters of mercury
MM Medical Monitor
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
NTCP sodium-taurocholate cotransporting polypeptide
NMR nuclear magnetic resonance spectroscopy
NOAEL no observed adverse event level
OATP Organic anion -transporting polypeptide
OLE Open Label Extension
PBC Primary Biliary Cholangitis
PBMCs peripheral blood mononuclear cell(s)
PD Pharmacodynamic
PK Pharmacokinetic
P-gp P-glycoprotein
PO taken by mouth
PRO Patient –Reported Outcome
PSC Primary Sclerosing Cholangitis
PT preferred term
PTC percutaneous transhepatic cholangiogram
PT prothrombin time
PTT Partial prothrombin time
QoL Quality of Life
RBC red blood cell count
RNA ribonucleic acid
RXR Retinoid X receptor
SADR serious adverse drug reaction
SAE serious adverse event
SAP statistical analysis plan
SF-36 Short Form (36) Health Survey
SOC System Organ Class
SOP standard operating procedure
SUSAR Suspected Unexpected Serious Adverse Reaction
t½ Time required for the terminal elimination half -life of the drug
TEAEs Treatment emergent adverse events
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page17 29 June 2016TGR5 bile acid receptor
TPO thrombopoietin
TR-FRET Time-resolved fluorescence resonance energy transfer
Tlast last measured concentration
Tmax time (observed time point) of C max
TNF tumor necrosis factor
UDCA ursodeoxycholic acid
UGT uridine dophosphate glucuronosyltransferase
ULN upper limit of the normal range
US United States
Vss Volume of distribution at steady state
VAS visual analog scale
WBC white blood cell count
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page18 29 June 20161. INTRODUCTION
1.1. Background
Primary Sclerosing Cholangitis ( PSC)is a chronic biliary  disease of unknown etiology  
characterized b y a fibrosing cholangitis that leads to inflammation, cholestasis and cirrhosis. The 
overall incidence of PSC is 0.77 per 100,000 person- years, with a median age at diagnosis of 
41years and 2-to-1 male to female predominance {Molodeck y et al 2011 }.PSC is highly  
associated with inflammatory  bowel disease (IBD), ty pically ulcerative colitis (UC) with up to 
90% of PSC patients having associated IBD and conversel y,PSC develops in approximately  8% 
of all IBD patients {Saich et al 2008}. There are approximately  30,000-45,000 patients with PSC 
in the United States, making it an orphan disease. PSC affects less than 1.6 in 10,000 people in 
the European Union (EU), equivalent to a total of fewer than 82,000 people. 
PSC is a progressive disease that leads to cirrhosis of the liver. The clinical presentation of PSC 
is variable, and ranges from asy mptomatic disease with mild elevations in alkaline phosphatase 
(ALP) and transaminases to more rapidl y progressive, symptomatic disease in 15 -30% of all 
patients. I n addition to complications related to cirrhosis and portal h ypertension, patients with 
PSC are prone to repeated episodes of bacterial cholangitis, pruritus, and are at high risk for 
cholangiocarcinoma. Specifically, the lifetime risk of cholangiocarcinoma in patients with PSC 
is 10-15%, a rate 160 -fold t
hat of the general population {Saich et al 2008 }. Mortality  from PSC 
is estimated to be 35% over 10 years from diagnosis {Kornfeld et al 1997 }
.
There are no approved therapies for PSC. Medical therap y with ursodeox ycholic acid (UDCA) 
may improve liver biochemistry , but has no impact on sy mptoms or clinical outcomes {Triantos 
et al 2011 }.Immunosuppressive therapy has also been ineffective {Lindor et al 2015}. Episodes 
of ascending cholangitis are managed supportively with a ntibiotics in conjunction with 
therapeutic drainage if necessary . Liver transplantation is the only  therapeutic option currentl y 
available to patients with PSC. Outcomes of transplantation are generall y favorable (five -year 
survival ~85%), but the disease recur spost-transplant in up to 25% of patients {
Graziadei et al 
1999}.
The etiology  of PSC is unknown. As noted above, there is a strong association with IBD and 
genome-wide association studies (GWAS) indicate moderate genetic associations with PSC. The 
strongest associations are in the HLA complex on chromosome 6p21 with weaker associations at 
loci known to be associated with IBD, chromosome 3p21, 2q35 and the GPC5/GPC 6 region on 
chromosome 13q31 {Karlsen et al 2010}. Several hy potheses as to the underly ing cause of the 
disease have been propose d including aberrant homing of T cells to the bile ducts, autoimmunity , 
bile acid toxicity , and gut bacterial translocation leading to fibrosing cholangitis, and subsequent 
cholestasis and hepatotoxicity .
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page19 29 June 20161.2. GS-9674
1.2.1. General Information
GS-9674 is a potent ago nist of Farnesoid X Receptor (FXR) whose activity  in intestinal 
epithelial cells results in the release of fibroblast growth factor 19 ( FGF19). FGF19 is an 
endocrine peptide which drives a signaling cascade to decrease hepaticlipogenesis, 
gluconeogenesis, triglyceride accumulation, and bile acid s ynthesis.
Please refer to the Investigator’s Brochure (IB) for additional information on GS-9674 including:
In Vitro FXR agonism
Nonclinical Pharmacokinetics and In Vitro Metabolism
Nonclinical Pharmacology and Toxicology
1.2.2. Nonclinical Toxicology
The nonclinical toxicity  profile of GS -9674 has been assessed in mice and cy nomolgus monkey s 
administered GS-9674 orally  for 4 weeks in both species and for 13 weeks in monkey s and 
26weeks (in -life phase only) in mice. GS-9674-related effects includednon-adverse findings in 
the liver for both species that are likel
y related to the pharmacology of the compound. I n both 
mice and cy nomolgus monkey s, mild increases in alkaline phosphatase ( ALP)activity, liver 
weight, and hepatocellular hy pertrophy were observed after 4 weeks of dosing.Minimal oval cell 
hyperplasia was also observed in the liver of cy nomolgus monkey safter 4 weeks of dosing. The 
increases in ALP activity and liver weights persisted but did not progress with l onger term 
dosing in monkey s (13 weeks) but the histopathological changes were no longer evident. In 
mice, the AL P activity  and liver weights were still present and were modestly  more pronounced 
with longer term dosing (26 weeks). In mice, the above findin gs were observed at 
≥100mg/kg/day after 4 weeks of dosing and at all doses ( ≥ 20 mg/kg/day ) after 26 weeks of 
dosing.  In monkey s, the above findings were observed at doses of 300 mg/kg/day  after both 
4 and 13 weeks of dosing. Decreases in cholesterol (≥ 60 mg/kg/day) and trigl ycerides 
(≥ 100mg/kg/day ) as well as increased albumin ( ≥ 60mg/kg/day) observed in mice after 
4and/or 26 weeks of dosing as well as the decrease in serum bile acids (300 mg/kg/day ) in 
monkey after 13 weeks of dosing are also likel y to be related to the pharmacology of GS-9674.
Other minimal to mild, non-adverse findings observed after 13 or 26 weeks of dosing in 
monkeys or mice, respectively , that were considered GS-9674-related included decreased red 
blood cell parameters (mouse; ≥ 20 mg/kg/day ), increased platelets (mouse; 600/300 mg/kg/day ), 
shortened activated partial thromboplastin time (monkey ; 300 mg/kg/day ), and increased 
phosphorus (mouse; 600/300 mg/kg/day ). Findings present in monkey s after 13 weeks of dosing 
were reversi ble after a 4 week nondosing recovery  period. In the 26 week mouse study , there 
were no adverse findings based on the in- life data at 60 mg/kg/day  and the no -observed-adverse 
effect level (NOAEL) in monkey s after 13 weeks of dosing was 300 mg/kg/day . 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page20 29 June 2016Preliminary steady-state PK data from Cohort 5 (administration of GS -9674 100 mg with food) 
in the ongoing Phase 1 study of GS-
9674 (GS-US-402-1851: Section1.2.5.1) indicate adequate 
safety margins based on GS-9674 exposures at the nonclinical NOAEL doses in mouse and 
cynomolgus monkey  (Table1-1).
Table1-1. Exposure Margins for GS-9674 Based on Observed GS-9674 
Exposure A fter Administration of 100mgGS-9674 QD U nder Fed
Conditions at Steady -State in Cohort 5Compared to Exposures 
Observed at NOAEL D oses in Mouse and Cynomolgus Monkey 
SpeciesNOAEL
Exposure MarginaDose 
mg/kg/dayAUCtau
µg*hr/mL
Mouse 60b110 22
Cynomolgus Monkey 300 110 22
aCalculated using observed human AUCtauof 5.02µg*hr/mLat 100 mg QD dose administ ered fed from cohort 5 in 
StudyGS-US-402-1851.
1.2.3. Nonclinical Pharmacology
GS-9674 is a potent and selective agonist of FXR. This conclusion is supported by  the following 
data:1) modeling demonstrated an interaction of GS-9674 with the binding domain of FXR /
Retinoid X receptor (RXR) consistent with agonist activity , 2) GS-9674 induced an agonist 
response in a time -resolved fluorescence resonance energy  transfer (TR -FRET)biochemical 
assay with an EC 50of 16nM, which was comparable to that of other known FXR agonists, and 
3) GS-9674 did not activate the structurally  similar bile acid receptor TGR5, did not activate 
other nuclear hormone receptors, and did not bind to a pan el of other off -target receptors and 
enzymes.
The cellular potency  of GS-9674 to activate FXR -mediated transcription was characterized using 
a firefly luciferase reporter gene engineered under the control of a FXR/RXR response element 
(PC-402-2012). GS -9674 caused complete FXR activation with an EC 50value of 43 nM, which 
was more potent than chenodeox ycholic acid (EC 50of 1770 nM).
Oral dose -ranging experiments in male cy nomolgus monkey s demonstrated maximal increases in 
plasma FGF19 at a dose of 5 mg/kg (PC-402-2016). In addition, the oral administration of 
GS-9674 (30 mg/kg) to cy nomolgus monkey s directly activated intestinal FXR, as measured b y 
the expression of FXR -target genes in the ileum (15- fold increase in FGF19 mRNA, and a 2 -fold 
increase in organic solute transporter (OST α and OSTβ mRNA) (PC -402-2005).
The effects of GS-9674 on FGF19 levels were compared in cy nomolgus monkey s following both 
oral and intravenous (IV) administration (PC -402-2016). Despite greater exposures following IV 
administration, only  the oral administration of GS -9674 increased circulating FGF19 levels. 
These data suggestthat intestinal FXR agonism by GS-9674 causes FGF19 production, whereas 
low systemic free drug concentrations limit effects following IV administration o f GS-9674.
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. Final 
Original 
GS-9674 was evaluated in a choline-deficient high fat diet/NaN0 2 rat model of liver fibrosis 
(PC-402-2015). This in vivo model utilized "2 hits" to mimic the metabolic and oxidative stress 
components ofNASH disease in humans {Nakamoto et al2009}, {Murakami et al2013}. Treatment 
with GS-9674 dose-dependently reduced both biochemical and histological measures of liver 
fibrosis in this model. 
Safety pharmacology studies have been conducted to examine the potential effects ofGS-9674 
on the cardiovascular (CV), respiratory, and central nervous system (CNS) systems. There were 
no GS-9674-related effects on the CNS or respiratory system in mice administered up to 
600 mg/kg. In addition, there was no significant human ether-a-go-go-related gene inhibition at 
concentrations up to 100 J.lM or GS-9674-related effects on the CV system in monkeys 
administered up to 300 mg/kg. 
Overall, the results from these pharmacology studies demonstrate that GS-9674 is a potent and 
selective agonist of intestinal FXR with the potential to benefit patients with PSC by inducing 
FGF19 production and reducing bile acid levels. 
1.2.4. Non clinical Phannacokinetics 
when dosed as 
pH-dependents 
GS-9674 absorption. 10% and 20% 
. Low, 
limiting 
The low systemic clearance (CL) of GS-9674 in rats, dogs and monkeys was considerably lower 
than the predicted hepatic clearance based on in vitro studies with hepatocytes. This discrepancy 
is most likely a result of protein-restricted clearance in vivo due to the very high plasma protein 
binding( > 99.6%) across species. The volume of distribution (V ss) ofGS-9674 was consistent 
with extracellular fluid (ranging from 0.16-0.21 Llkg) in rats, dogs, and monkeys. 
After oral dosing to albino and pigmented mice, C4C] GS-9674-derived radioactivity was 
distributed to most of the tissues, with the highest maximum concentrations of radioactivity 
determined in organs of absorption and excretion. Generally similar distribution patterns and 
tissue concentrations of C4C]GS-9674-derived radioactivity were observed in albino and 
pigmented mice with no observed binding to melanin. In both strains, no quantifiable 
radioactivity was detected in brain, suggesting C4C] GS-9674-derived radioactivity did not cross 
the blood-brain barrier. Fecal elimination was a predominant route of elimination of C4C] 
GS-9674-derived radioactivity in both mice (85.7% and 5.45% recovered in feces and urine, 
respectively) and monkeys (78.2% and 69.7% recovered in feces in intact and bile duct 
cannulated animals) likely representing drug not absorbed from the gastrointestinal tract. 
Approximately 6% of the administered radioactivity was excreted in bile and urine in monkeys. 
Radiolabeled material was primarily excreted within the first 48 hours. 
GS-9674 undergoes oxidative metabolism in human hepatocytes. Comparison of metabolism in 
hepatocytes from mice, rats, dogs, monkeys, and humans did not identify any metabolites unique 
to humans, supporting the selection of mice and monkeys for the assessment of the toxicology of 
CONFIDENTIAL Page 21 29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page22 29 June 2016GS-9674. Of the recombinant human CYP isozy mes tested, CYP2C8, CYP3A4, and CYP2C19 
were shown to metabolize GS -9674. Potent inhibitors of these CYPs therefore may  affect 
metabolism of GS -9674. GS -9674 had little inhibitory  effect on the activities of CYP1A2, 
CYP2B6, CYP2C19 or CYP2D6 (I C50>25μM). For CYP2C8, CYP2C9, and CYP3A, I
C50
values of 2.4 to 13.6 μM were obtained but GS -9674 was not a mechanism -based inhibitor of 
these enzy mes. GS-9674 showed mode rate inhibition of human UGT1A1, sodium -taurocholate 
cotransporting poly peptide (NTCP), and bile salt export pump (I C502.8-7.7μM). GS-9674 
inhibited human OATP1B1, OATP1B3, and OATP2B1 with I C50values of 0.68, 0.41, and 
0.21μM, respectivel y. GS-9674 th
erefore has the potential to affect hepatic/intestinal uptake of 
OATP substrates or metabolism of CYP2C8, CYP2C9, or CYP3A4 substrates when its 
concentrations are sufficiently  high. However, low solubility , high protein binding (> 99.98%) 
and low sy stemic levels reduce the potential for GS-9674 to cause drug -drug interactions via 
inhibition of metabolic enzy mes and transporters.
GS-9674 was a substrate for efflux transporters P- glycoprotein and breast cancer resistance 
protein, as well as the uptake transpo rters OATP1B1, 1B3, and 2B1, and NTCP. I nhibitors or 
genetic pol ymorphisms affecting the activity  of these transporters may  affect GS-9674 intestinal 
absorption and hepatic uptake. This was illustrated in an in vivo study  in monkey s where 
pretreatment with cyclosporin A, a known inhibitor of efflux transporters, increased the 
bioavailability  of GS-9674 approximately  5-fold.
GS-9674 is highly  selective for FXR over other nuclear hormone receptors in cell -based reporter 
assays, including those associated with potential for induction of human drug metabolizing 
enzymes and transporters (eg, pregnane X receptor, constitutive androstane receptor). Thus the 
liability of GS-9674 to cause drug -drug interactions through proteins regulated by  these nuclear 
receptors is low.
1.2.5. Clinical Trials of GS-9674
Ongoing clinical experience with GS-9674 includes a Phase 1 clinical study  (GS-US-402-1851).  
A brief PK summary  of results from this ongoing study  is presented below.
1.2.5.1. GS-US-
402-1851
StudyGS-US-
402-1851 is an ongoingPhase 1, randomized, placebo -controlled, single -and 
multiple-dose study  with 4 prespecified, staggered dose -escalation cohorts and 4 randomized, 
placebo-controlled, single- and multiple -dose cohorts with adaptive dose selection and dose 
frequency .
Preliminary data based on an interim safet y analysis as of 22 June 2016 areprovided in the 
following sections.Atotal of 105 subjects have been randomized into 7 cohorts. Onesubject 
withdrew consent after randomization but prior to dosing and was not replaced . Therefore, safet y 
data described below includes 104 dosed subjects.
Subjects received single and multiple doses of GS-9674 at a dose of 10 mg QD (Cohort 1), 
30mg QD (Cohort 2), 100mg QD (Cohort 3), or 300 mg QD (Cohort 4) administered in a 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page23 29 June 2016fasting stat e, or GS-9674 100 mg QD administered in a fed state (Cohort 5), GS-9674 50 mg 
BID (Cohort 6) , or15mg BID (Cohort 7). A summary  of treatment -emergent adverse events 
(AEs) is provided in Table1-2.Overall, the rate of any  AEs wassimilar between subjects treated 
with GS-9674 or placebo. All AEs were Grade 1 or 2 in severit y; AEs occurring in greater than 
twoGS-9674 treated subjects were back pain (n =5), diarrhea (n=3), and headache (n =6).
Table1-2. Preliminary Safety Summary of Subjects Following Single -and 
Multiple-Dose Administration of GS-9674 Under Fasting or Fed 
Conditions in Healthy Volunteers ( GS-US-
402-
1851)
Cohort 1: 
10mg 
QD 
Fasted
(N = 12)Cohort 2: 
30mg 
QD 
Fasted
(N = 12)Cohort 3: 
100mg 
QD 
Fasted
(N = 12)Cohort 4: 
300mg 
QD 
Fasted
(N = 12)Cohort 5:      
100mg
QD
Fed       
(N = 12)Cohort 6: 
50mg 
BID
(N = 11a)Cohort 7: 
15mg 
BID
(N = 12)Pooled 
Placebo
(N = 21)
Treatment-
Emergent 
Adverse 
Event4(33%) 3(25%) 4(33%) 3(25%) 5(42%)3(27%)4(33%) 5(24%)
Treatment-
Emergent 
Adverse 
Event 
Related to 
Study 
Drug0 (0%)   0 (0%) 0 (0%) 0 (0%) 1 (8%) 0 (0%) 1 (8%) 0 (0%)
Grade 3 or 
4 
Treatment-
Emergent 
Adverse 
Event0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Grade 2,3, 
or 4 
Treatment-
Emergent 
Adverse 
Event0 (0%) 1 (8%) 1 (8%) 0 (0%) 1 (8%) 0 (0%) 0 (0%) 0 (0%)
a 1 subject withdrew consent after randomization prior to dosing and was not replaced.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page24 29 June 2016Grade 2 or 3 elevations in serum alanine aminotransferase (ALT) were seen in five(6%) 
GS-9674 treated subjects and one(5%) placebo treated subject. Of these, twoGS-9674 treated 
subjects were noted to have grade 2 or 3 elevations of ALT during active treatment; oneeach in 
Cohort 6 ( GS-9674 50 mg BID) and Cohort 7 ( GS-9674 15 mg BID). The remaining subjects 
with elevated ALT were identified at the follow- up visit 4 day s after completing study  drug.In 
two of these subjects, elevated ALT was associated with very  high serum creatine kinase levels, 
consistent with elevation due to strenuous exercise. All ALT elevations returned to baseline and 
were not associated with changes in bilirubin or coagulatio n parameters. There were no clinically  
important treatment- or dose-related trends in vital signs, ECG , or physical examination findings
in this study .
Preliminary  PK parameters for GS-9674 after single -and multiple -dose administration of 10, 30, 
100 or 300 mg under fasting conditions and 100 mg under fed conditions in healthy  volunteers 
are presented in Table1-3. GS-9674 was rapidl y absorbed with a median T maxoccurring between 
1.25 and 3.25 hours under fasting conditions. Across the dose levels tested, plasma 
concentrations declined in a bi-
phasic manner with a median t 1/2of 5.56 to 12.8 hours . The lower 
observed median t1/2of 5 to 6 hours in the 10 mg and 30 mg cohorts , respectively ,may be a 
result of plasma concentrations falling below the limit of quantitation during the distributional 
phase of the profile. In general, GS-9674 AUC and C maxincreased less than dose proportionally 
above 10 mg upon single and multiple dosing. As expected based on the short GS-9674 t 1/2and 
oncedaily dosing, minimal to no accumulation was observed for GS-9674 AUC, C maxor C24
from single to multiple dose administration. Administration of GS-9674 with food resulted in 
prolonged absorption of GS-9674 with an approximately  60% reduction in mean C maxand 
approximately  35% reduction in mean AUC.   
Plasma concentrations of GS-716070 (a metabolite 
of GS-9674 with ~40- fold less potency  than GS-9674 against FXR) were analy zed in Cohort 5 
(GS-9674 100 mg administered fed).  The t 1/2of GS-716070 was similar to that of GS-9647 with
AUC and C max~60% and 35%, respectively  of that observed for GS-9674.  Similar to GS-
9674, 
GS-716070 did not accumulate upon multiple dosing.  
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page25 29 June 2016Table1-3. Preliminary Plasma Pharmacokinetic Parameters of GS-9674 
Following Single -and Multiple -Dose Administration of GS-9674 
Under Fasting or Fed Conditions in Healthy Volunteers 
(GS-US-402-1851)
Parameter 
Mean (%CV)Cohort 1: 
10mg Fasted
(N = 12)Cohort 2: 
30mg Fasted
(N = 12)Cohort 3: 
100mg Fasted
(N = 12)Cohort 4: 
300mg 
Fasted
(N = 12)Cohort 5: 
100mg Fed
(N = 12)
Single 
DoseAUCinf 
(ng*h/ml)1260 (30.3) 2480 (37.2) 7740 (93.9) 12,500 (33.9) 5020 (40.4)
Cmax (ng/ml) 304 (41.6) 580 (48.9) 2590 (118) 3060 (66.2) 928 (58.3)
C24(ng/ml) 2.61 (49.9)b6.04 (35.7) 23.5 (40.0) 76.0 (67.4) 26.8 (42.3)
Tmax(h)a 3.00
(2.38, 4.00)3.00
(2.38, 3.63)1.75
(1.38, 2.63)1.25
(1.00, 3.13)3.75
(2.88, 4.25)
T1/2 (h)a 5.56
(5.46, 6.41)8.10
(5.74, 9.58)11.2
(8.30, 11.9)12.4
(11.4, 13.9)10.9
(8.87, 11.6)
Multiple 
DoseAUCtau 
(ng*h/ml)1280 (35.8) 2890 (23.5) 6720 (59.2) 8490 (48.8) 4180 (46.8)
Cmax (ng/ml) 322 (42.4) 718 (32.8) 2230 (75.9) 2330 (81.5) 819 (53.4)
Ctau (ng/ml) 2.75 (55.5) 7.90 (50.3) 36.3 (42.5) 70.1 (56.3) 22.6 (37.4)
Tmax(h)a 2.50
(1.50, 3.50)3.00
(1.88, 3.13)1.50
(1.00, 2.63)3.25
(1.00, 5.00)3.50
(3.00, 4.25)
T1/2 (h)a 6.75
(5.64, 8.45)5.95
(5.54, 6.55)8.99
(6.84, 11.49)12.8
(10.0, 14.7)13.1
(10.3, 15.0)
Pharmacokinetic parameters are presented as Mean (%CV), and shown to 3 significant digits 
a T maxand T1/2 are presented as median (Q1, Q3)
bN=11
Preliminary  changes in FGF19 and C4 levels as measured b y theprimary PD parameters (AUC 2-
8, Cmax, and C min)weredetermined to be the most sensitive measures of changes in FGF19 and 
C4 after multipledose administration of placebo, 10, 30, 100 or 300 mgGS-9674under fasting 
conditions and 100 mg under fed conditions in healthy  volunteers are presented in Table1-4. In
general, similar changes in PD parameters were observed after single or multiple dose 
administration (single dose data not shown). GS-9674 doses > 30 mg significantly  increased 
FGF19 AUC 2-8and Cmaxand reduced C4 AUC 2-8and Cmax. Administration of 100 mgGS-9674 
with food resulted in prolonged elevation of FGF19 plasma concentrations compared to 
administration of GS-9674 100 mg under fasting conditions. Across the dose range of 10 to 
300mg GS-9674 administered fasted, GS-9674 exposure was weakl y correlated with changes in 
FGF19and moderatel ycorrelated with changes in C4 ( Spearman correlation r = 0.45, p=0.00 2). 
Additionally , FGF19 and C4 AUC 2-8changes were inversely correlated (r = - 0.335, p=0.02).
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page26 29 June 2016Table1-4. Preliminary Pharmacodynamic Parameters (FGF19 and C4) 
Following Multiple -Dose Administration of Placebo, or GS-9674 
Under Fasting or Fed Conditions in Healthy Volunteers 
(GS-US-402-1851)
PD Parameter Ratio 
Compared to Day -
1
GeoMean (%CV)Placebo GS-9674
Fasted
(N=12)Fed
(N=3)10mg 
Fasted
(N=12)30mg 
Fasted
(N=12)100mg 
Fasted
(N=12)100mg 
Fed
(N=12)300mg 
Fasted
(N=12)
FGF19Day 
20AUC2-81.35
(53.9)0.77 
(32.7)3.07
(71.9)*3.99
(42.0)*3.61
(26.9)*2.30 
(40.1)*3.94
(62.0)*
Cmax1.21
(48.0)0.73 
(45.2)2.05
(94.6)*2.39
(45.9)*2.32
(44.9)*2.24 
(31.1)*3.08
(57.0)*
C4Day 
20AUC2-81.24
(93.8)0.98 
(41.9)0.67
(86.8)*0.39
(57.1)*0.50
(101)*0.69 
(71.3)0.33
(97.8)*
Cmin1.29
(78.7)1.08 
(42.6)0.78
(59.3)0.37
(59.6)*0.71
(72.6)*0.45 
(80.5)*0.44
(76.3)*
Pharmacodynamic parameters are presented as geometric mean ratio (arithmetic %CV), and shown to 3 significant digits
* p<0.05 compared to placebo
1.3. Rationale for t his Study
PSCis a disorder of unknown etiology  characterized by  inflammation and fibrosis of the 
intrahepatic and extrahepatic bile ductsthat result in the impairment of bile flow (cholestasis). 
Accumulation of excess bile acids causes hepatocellular cy totoxicity  that leadsto progressive 
liver fibros isand cirrhosis .In pre-clinical and clinical studies, FXR agonism has been shown to 
reduce bile acid levels via FGF19 -mediated suppression of cholesterol -7-alpha-hydroxylase 
(CYP7A1), the rate -limiting enz yme in bile acid biosy nthesis{Inagaki et al 2005 }, {Pellicciari et al 
2002}, {Mudaliar et al 2013 }. In addition, in a murine model of fibrosis caused by  administration
of a methionine choline deficient diet and sodium nitri te injections, GS-9674 has demonstrated 
an anti-fibrotic effect. Thus ,GS-9674 is postulated to be beneficial in subjects with P SC .  
This study  will evaluate the safet y, tolerability , and efficacy  of 30mg and 100mg GS-9674 
administered with food f or 12weeks in subjects with PSC . The doses were selected based on 
short-term safety , PD and PK results from S tudy GS-US-402- 1851 in healthy  subjects. 
Across the range of GS-9674 doses evaluated (10 to 300mg QD), doses >30 mg provide 
comparable intestinal FXR agonismassessed byincreases in plasma FGF19 exposure. Food, by  
slowing oral absorption of GS -9674, results in prolonged elevation of plasma FGF19 
concentrations. Exposure -response relationships show that changes in C4 exposure are 
negatively correlated w ith changes in FGF19 exposu re as well as GS -9674 exposure. Based on 
these results, GS-9674 doses of 30 and 100 mg with food are selected for further study  as they 
are expected to 1) provide enteral FXR agonism, reductions in bile acid pools, and liver 
biochemical improvements in subjects with P SC; and 2) inform regarding the impact of 
increasing s ystemic GS-9674 exposure on safet y and efficacy.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page27 29 June 2016In the Phase 1 stud y,GS-US-402-1851, GS -9674 was tested at doses up to 300 mg once dail y for 
up to 14 day s and was well-tolerated. Taken together, these data support the evaluation of 
GS-9674 30 and 100 mg in subjects with PSC.
Inclusion criteria for this study  were developed in order to identify  subjects with PSC who have 
persistently  abnormal blood markers of liverbiochemistry  but without cirrhosis. These subjects 
are at an increased risk of PSC -related complications including the need for liver transplantation 
and death. Subjects with clinical and histologic evidence of cirrhosis will be excluded from this 
study due to the uncertain PK and PD properties of GS-
9674 in the setting of subjects with 
cirrhosis. Targeting interventions in the proposed study  population will provi de evidence for the 
safety and efficacy of GS-9674 in subjects at risk for progressive hepatic fibrosis and cirrhosis.
1.3.1. Risk/Benefit Assessment for the Study 
Potential risks of a participant’s study  involvement include unknown AEs, general risks 
associated with frequent clinic visits and laboratory  blood draws, and the associated pain and 
discomfort of phlebotomy. Strategies to mitigate these risks include close monitoring of lab 
values as well as AEs.
It should be noted that there are no currently  approved therapies specifically  for the treatment of 
PSC. The only  therapeutic option available to PSC subjects with advanced liver disease is liver 
transplantation .
Subjects with PSC randomized to the placebo control arm in the study  may benefit from frequent 
med
ical monitoring and close assessment of their PSC and associated pathologies during the 
duration of placebo treatment. Subjects randomized to GS-9674 and those who receive GS-9674 
as part of the OLE phase, may benefit from an improvement in their underl ying PSC which may  
manifest as improvements in liver biochemistry , measures of fibrosis, or improvements in quality  
of life. Importantl y, this study will provide further data to inform the clinical development of the 
investigational medicinal product GS-9674 for use in an area of unmet medical need. 
Overall, the nonclinical and limited preliminary
 clinical data show a positive benefit/risk ratio in 
support of the study  in subjects with PSC. The study  will be conducted in accordance with GCP 
and all applicable rules and regulations. Appropriate safety monitoring will be conducted 
throughout the stud y to further characterize the safety profile of GS-9674 in subjects without 
cirrhosis due to PSC.
1.4. Compliance
This study  will be conducted in compliance with this pro tocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
2. OBJECTIVES 
The primary objective of this study is as follows: 
• To evaluate the safety and tolerability of GS-9674 in subjects with PSC 
The exploratory objectives ofthis study are as follows: 
IT 
I 
I 
I I 
I 
I 
I 
I 
I 
CONFIDENTIAL Page 28 -Final 
Original 
29 June 2016 
GS-9674
Protocol GS-US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page29 29 June 20163. STUDY DESIGN
3.1. Study Design
This is a Phase 2 randomized, double -blind, placebo -controlled study  evaluating the safet y, 
tolerability , and efficacyof GS-9674 in subject s with PSC without cirrhosis.
The study  will consist of 2 phases, a Blinded Study Phase and an OLE Phase. 
Blinded Study  Phase: Includes a 4 -week screening period, 12 -weeks of blinded treatment, and a 
Blinded Study  Phase Follow up visit 4 weeks after compl etion of blinded treatment. 
Subjects completing the Blinded Study  Phase without permanentl y discontinuing study drug will 
be eligible to participate in the OLE Phase of the study .
OLE Phase: Includes a 96 -week OLE and an OLEPhase follow-up visit 4weeks after 
completion of open label treatment.
The overall study  design is presented graphicall y in Figure 3-1.
Figure 3-1. Overall Study Design 

GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page30 29 June 20163.2. Treatment Plan and Regimen
Subjects meeting the study ’s entry criteria will be randomly  assigned in a 2:2:1 ratio to 1 of 3 
different treatment groups during the Blinded Study  Phase as shown in Figure 
3-1. 
Randomization will be stratified b y the presence or absence of UDCA use.
Study drug(s)will be administered for a total of 12 weeks from the Baseline/Day 1 visit during 
the Blinded S tudy Phase and 96 weeks during theOLE Phase. Subjects will begin open -label 
treatment with GS-9674(100mg po daily ). The dose of GS-9674 may  be reduced from 100 mg 
to 30mg (or subsequ ently increased back to 100 mg) at the PI’s discretion with the approval of 
the MM,as required.
Subjects will be unblinded to their Blinded Study  Phase treatment assignment after the primary  
analysis has been completed, approximately  6 weeks after all subjects have completed the 
Blinded Study  Phase.
Dosage and administration of the study  drug(s)and reference product are described in 
Section5.3
.
3.3. Biomarker Testing
3.3.1. Biomarker Samples to Address the Study Objectives:
Biological specimens will be collected in this study as per the study  procedures table
(Appendix 2
)and will be used to evaluate the association of ex ploratory systemicbiomarkers 
with study  drug response, including efficacy  and/or adverse events and to increase knowledge 
and understa nding of the biology  of PSCor related diseases such as Primary Biliary  Cholangitis 
(
PBC)and/or the validation of a companion diagnostic forPSC. B ecause biomarker science is a 
rapidly evolving area of investigation, and adverse events in particular are difficult to predict, it 
is not possible to specify  prospectivel y all tests that will be done on the specimens provi ded.  The 
testing outlined is based upon the current state of scientific knowledge. It maybe modified 
during or after the end of the study  to remove tests no longer indicated and/or to add new tests 
based upon the growing state of art knowledge. Samples will be destroy ed no later than 15 y ears 
after the end of the stud y.
Biomarker testing can include biomarkers that monitor auto-antibodies c
haracteristic of PS C, and 
markers of bone metabolism .In addition biomarkers such as biochemicals, biological 
macromolecules, naturally  occurring metabolites, and biomarkers of FXR activity  (e.g. FGF19, 
C4 and bile acids) can also be determined.
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
3.3.2. Biomarker Samples for Optional Future Research 
PPD 
3.3.3. Biomarker Samples for Optional Genomic Research 
PPD 
PPD 
CONFIDENTIAL Page 31 Final 
Original 
29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page32 29 June 20164. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
This study  will enroll approximately 50adults, between 18 -70 years oldwith non-cirrhotic P SC.
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1) Males and females between 18-70 years of age; inclusive based on the date of the screening 
visit;
2)Willing and able to give informed consent prior to any stud y specific procedures being 
performed;
3)Diagnosis of PSC based on cholangiogram (magnetic resonance cholangiopancreatograph y 
[MRCP], endoscopic retrograde cholangiopancreatograph y [ERCP], or percutaneous 
transhepatic cholangiogram [PTC]) within the previous 12 months;
4)Serum AL P >1.67 x ULN;
5)For subjects on UDCA, the dose of UDCA must have been stable for at least 6months 
beforescreeningthroughthe 
end of the treatment. For subjects not on UDCA, no UDCA use 
for at least 6 month before screening through the end of the tr eatment;
6)For subjects being administered biologic treatments (eg, anti -tumor necrosis factor (TNF) or 
anti-integrin monoclonal antibodies), immunosuppres sants orsystemic corticosteroids, the 
dose must have been stable for at least 3 months prior to screeningand anticipated to remain 
stable throughout the trial;
7)Screening FibroSURE/FibroTest®<0.75;
8) Platelet count ≥ 100,000/mm3;
9)Creatinine Clearance (CrC L) as calculated by  the Cockcroft -Gault equation ≥ 60 ml/min;
10)Females of childbearing potential (as defined in Appendix 4) must have a negative serum 
pregnancy  test at the Screening visit and a negative urine pregnancy  test on the Baseline/Day  
1 visit prior to the first dose of study  drug;
11) All female subjects of childbearing potential who engage in heterosexual intercourse must 
agree to use a highl y effective method of contraception from the screening visit throughout 
the study period and for 30 day s following the last dose of study  drug(s) (see definition in 
Appendix 4)
;
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page33 29 June 201612)Male subjects with female partners of childbearing potential must use condoms during 
treatment and for 90 day s after the last dose of study  drug(s)(see Appendix 4for details);
13) Male subjects must agree to avoid sperm donation from Baseline/Day  1 visit throughout the 
study period and for 90 days after the last dose of study  drug(s)(see Appendix 4for 
details);
14) Female subjects must refrain from egg donation and in-vitro fertili zation during treatment 
and until at least 30days afterthelast dose of study  drug(s)(see Appendix 4for details);
15)Willing and able to comply  with scheduled visits, drug administration plan, laboratory  tests, 
liver biopsies, other study procedures, and study restrictions ;
16)Must be able to read and complete QoLquestionnaires independently .
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolledin this study .
1) Pregnant or lactating females ; lactating females must agree to discontinue nursing before the 
study drug (s) is administered;
2)ALT > 10xULN;
3)Total bilirubin > 2x UL N;
4)INR >1.2 unless on anticoagulant therap y;
5)Serum albumin < 3.0 g/dL;
6)Cirrhosis of the liver as defined b y any of the following:
a)Historical liver biopsy  demonstrating stage 4 fibrosis according to the Ludwig 
classification (or equivalent) 
b) History of decompensated liver disease, including ascites, hepatic encephalopathy  or 
variceal bleeding
c)Liver stiffness >14.4 kPa by  FibroScan;
7)Small-duct PSC ( histologic evidence of PSC with normal bile ducts on cholangiograph y);
8) Other causes of liver disease including secondary sclerosing cholangitis and viral, metabolic, 
alcoholic, and other autoimmune conditions .
9)Positive anti -mitochondrial antibody;
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page34 29 June 201610)History of liver transplant ation;
11)History of hepatocellular carcinoma or cholangiocarcinoma. If a dominant stricture is found, 
cholangiocarcinoma must be excluded prior to randomization;
12)Ascending cholangitis within 60 days of screening;
13)Presence of a percutaneous drain or bile duct stent;
14)Chronic hepatitis B (HBsAg positive);
15)
Chronic hepatitis C (HCV antibody andRNA positive);
16)HIV Ab positive;
17)Current active inflammatory  bowel disease (IBD) defined as a partial Mayo score of >2;
18)Known hy percoagulable condition o r history of venous or arterial thromboembolic disease;
19)Alcohol consumption greater than 21 oz/week for males or 14 oz/week for females 
(1oz/30mL of alcohol is present in 1 12oz/360mL beer, 14oz/120mL glass of wine, and a 1 
oz/30mL measure of 40% proof a lcohol);
20)History of intestinal resection or malabsorptive condition that may  limit the absorption of 
GS-9674. Prior cholecy stectomy and appendectomy  are permitted ;
21)Use of fibrates or obeticholic acid within 3 months prior toscreening through the end of 
treatment;
22)Positive urine screen for amphetamines, cocaine or opiates (i.e. heroin, morphine) at 
screening. Subjects on stable methadone or buprenorphine maintenance treatment for at least 
6months prior to screening may  be included in the study . Subjects with a positive urine drug 
screen due to prescription opioid
-based medication are eligible if the prescription and 
diagnosis are reviewed and approved b y the investigator ;
23)Unstable cardiovascular disease as defined b y any of the following:
a)Unstable angina within 6 months prior to screening
b)Myocardial infarction, coronary  artery bypass graft surgery or coronary  angioplasty  
within 6 months prior to screening
c)Transient ischemic attack or cerebrovascular accident within 6months prior to screening
d)Obstructive v alvular heart disease or h ypertrophic cardiom yopathy
e)Congestive heart failure ;
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page35 29 June 201624)Use of an y prohibited concomitant medications 28 days prior to Baseline/Day  1 through the 
treatment period as described in S ection 5.5of protocol;
25)History of a malignancy  within 5 years of screening with the following exceptions:
a)Adequatel y treated carcinoma in situ of the cervix
b)Adequatel y treated basal or squamous cell cancer or other localized non -melanoma skin 
cancer;
26)Any laboratory  abnormality  or condition that, in the investigator’s opinion, could adversely  
affect the safet y of the subject or impair the assessment of study results;
27)Participation in another investigational stud y of a drug or device within 1 month prior or 
within 5 half -lives of the prior investigational agent (whichever is longer) prior to screening;
28)Concurrent participation in another therapeutic clinical study ;
29)Known hy persensitivity  
to GS-9674, the metabolites, or formulation excipient;
30)Presence of an y condition that could, in the opinion of the invest igator, compromise the 
subject’s ability  to participate in the study , such as history  of substance abuse or a ps ychiatric
(including an y subjects with a psy chiatric hospital admission or emergency  room visit in the 
2 years prior to screening) or medical co ndition;
31)Unavailable for follow -up assessment or concern for subject’s compliance with the protocol 
procedures .
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
5. INVESTIGATIONAL MEDICINAL PRODUCTS 
5.1. Randomization, Blinding and Treatment Codes Final 
Original 
An Interactive Web Response System (IWRS) will be used for centralized randomization and 
treatment assignment. Randomization will be stratified by the presence or absence ofUDCA use. 
Investigative site personnel will obtain the subject's identification number and study drug 
assignment from the IWRS. Subjects and all personnel directly involved in the conduct of the 
study will be blinded to treatment assignment. 
Study drug(s) will be dispensed by the study pharmacist, or designee, in a blinded fashion to the 
subjects. 
5.1.1. Procedures for Breaking Treatment Codes 
In the event of a medical emergency where breaking the blind is required to provide medical care 
to the subject, the investigator may obtain treatment assignment directly from the IWRS system 
for that subject (refer to the Study Reference Binder for IWRS unblinding instructions). Gilead 
recommends but does not require that the investigator contact the Gilead medical monitor before 
breaking the blind. Treatment assignment should remain blinded unless that knowledge is 
necessary to determine subject emergency medical care. The rationale for unblinding must be 
clearly explained in source documentation and on the case report form/ electronic case report 
form ( eCRF), along with the date on which the treatment assignment was obtained. The 
investigator is requested to contact the Gilead medical monitor promptly in case of any treatment 
unblinding. 
Blinding of study treatment is critical to the integrity of this clinical trial and therefore, if a 
subject's treatment assignment is disclosed to the investigator, the subject will have study 
treatment discontinued. All subjects will be followed until study completion unless consent to do 
so is specifically withdrawn by the subject. 
Gilead Drug Safety and Public Health (DSPH) may independently unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (SUSARs ). 
5.2. Description and Handling ofGS-9674 and PTM GS-9674 
5.2.1. Formulation 
GS-9674 is supplied as 30 
contain GS-9674-02 
CONFIDENTIAL Page 36 29 June 2016 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. Final 
Original 
Placebo-to-match (PTM) GS-9674 tablets are identical in size, shape, color and appearance to 
their corresponding of active GS-9674 tablets. PTM GS-9674 tablets contain the 
followin · clients: 
5.2.2. Packaging and Labeling 
GS-9674 tablets and PTM GS-9674 tablets are packaged in white, high-density polyethylene 
(HDPE) bottles. Each bottle contains 30 tablets, silica gel desiccant, and polyester packing 
material. Each bottle is enclosed with a white, continuous thread, child-resistant screw cap with 
an induction-sealed, aluminum-faced liner. 
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements ofthe United States Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice -Annex 13 (Investigational Medicinal 
Products), and/or other local regulations. 
5.2.3. Storage and Handling 
Study drug GS-9674 and PTM GS-9674 tablets and PTM GS-9674 tablets should be stored at 
controlled room temperature of 25°C (77°F); excursions are permitted between 15°C and 30°C 
(59°F and 86°F). Storage conditions are specified on the label. 
Until dispensed to the subjects, all bottles of study drugs should be stored in a securely locked 
area, accessible only to authorized site personnel. To ensure the stability and proper 
identification, study drug(s) should not be stored in a container other than the container in which 
they were supplied. Consideration should be given to handling, preparation, and disposal through 
measures that minimize drug contact with the body. Appropriate precautions should be followed 
to avoid direct eye contact or exposure when handling. 
5.3. Dosage and Administration of GS-967 4/PTM GS-967 4 
GS-9674 and PTM GS-9674 tablets will be provided by Gilead Sciences. In order to maintain the 
blind, each subject will be supplied with 2 bottles of tablets during the blinded phase of the trial. 
One bottle will contain GS-9674 30 mg or PTM GS-9674 30 mg, the second bottle will contain 
GS-9674 100 mg or PTM GS-9674 100 mg. Dosing for each treatment group will be as follows: 
• Treatment Group A: GS-9674 30 mg (1 x 30 mg tablet)+ PTM GS-9674 100 mg (1 x PTM 
100 mg tablet) administered orally once daily with food 
• Treatment Group B: GS-9674 100 mg (1 x 100 mg tablet)+ PTM GS-9674 30 mg (1 x 
PTM 30 mg tablet) administered orally once daily with food 
• Treatment Group C: PTM GS-9674 30 mg (1 x PTM 30 mg tablet)+ PTM GS-9674 
100 mg (1 x PTM 100 mg tablet) administered orally once daily with food 
CONFIDENTIAL Page 37 29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page38 29 June 2016DuringtheOLE Phase of the studysubjects will be provided with 100mg bottles of GS -9674
only, unless reassig ned to 30 mg dose due to tolerability .
The dose of GS-9674 may  be reduced 
from 100 mg to 30 mg (or subsequentl y increased back to 100 mg) at the PI’s discretion with the 
approval of the MM, as required.
The study  drug dose should be taken at approximately  the same time each day with food
.
A dose will be considered missed if the subject cannot take the dose within 12hours of their 
regular dosing time. If a subject misses a dose, the subject should take their next dose at the 
regular dosing time.
5.4. Prior and 
Concomitant Medications
Concomitant use of certain medications or herbal/natural supplements with study  drugmay result 
in PK and/or PD interactions resulting in increases or decreases in exposure of study  drug(s)or 
these medications. 
Concomitant medications taken within 28 days of screening through the follow -up visit need to 
be recorded in the source documents and electronic Case Report Forms (eCRFs).
Subjects with co-morbid diseases requiring medication(s) must be taking the medication without 
a change in dose within 28 days of Baseline/Day  1.
5.5. Prohibited Medications
The following medications are prohibited from 28 day s prior to Baseline/Day 1 up to and 
including the day  of the last dose of study  drug:
Hematologic stimulating agents (e.g. ery thropoiesis- stimulating agents (ESAs); granulocy te 
colony stimulating factor (GCSF); thrombopoietin (TPO) mimetics)
Investigational agents or devices for an y indication
Concomitant use of certain medications or herbal/natural supplements (sensitive substrates, 
inhibitors or inducers of drug transporters P -gp, BCRP, or OATP, or the drug metabolizing 
enzyme CYP3A or inhibitors or inducers of CYP2C8) with study  drug(s) may  result in PK 
interactions resulting in increases or decreases in exposure of study  drug(s) or concom itant 
medications. Examples of representative medications which are prohibited from 28 days 
prior to Baseline/Day 1 through the treatment period are listed below in Table5-1
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page39 29 June 2016Table5-1. List of Prohibited Medications
Drug Class Agents Disallowed
Antibiotics Azithromycin, Clarithromycin, Erythromycin
Acid Reducing Agents Proton-Pump Inhibitors, H2 -Receptor Antagonists, Antacidsa
Alpha 1-Adrenoceptor Antagonists Alfuzosin
AnticonvulsantsbCarbamazepine, Clonazepam, Ethosuximide, Oxcarbazepine, 
Phenobarbital, Phenytoin,  
Antidiabetics Glyburide, Repaglinide
Antidepressants Trazodone
Antifungals Itraconazole, Ketoconazole, Voriconazole
Antigout Colchicine
AntimycobacterialsbRifamycins, Isoniazid
Cardiac Medications Amiodarone, Amlodipine, Bepridil, Digoxin, Diltiazem, 
Disopyramide, Dronedarone, Felodipine, Nicardipine, Nifedipine, 
Olmesartan, Ranolazine, Systemic Lidocaine, Telmisartan, 
Valsartan, Verapamil, Quinidine
Corticosteroids Dexamethasone, Fluticasone
Endothelin Receptor Antagonists Bosentan
Ergot Derivatives Dihydroergotamine, Ergonovine, Ergotamine, Methylergonovine
GI Motility Agents Cisapride
Herbal/Natural SupplementsbSt. John’s Wort, Echinacea. Milk thistle (i.e. silymarin), Chinese 
herb sho- saiko-to (or Xiao -Shai-Hu-Tang)
HMG-CoA Reductase InhibitorscAtorvastatin, Fluvastatin, Lovastatin, Pitavastatin , Pravastatin, 
Rosuvastatin, Simvastatin
Inhaled Beta Agonists Salmeterol
Phosphodiesterase Type 5 (PDE5) inhi bitors Sildenafil, Tadalafil, Vardenifil
Sedatives/Hypnotics Buspirone, Clorazepate, Diazepam, Estazolam, Flurazepam, 
Midazolam, Triazolam, Zolpidem
Selective Serotonin Reuptake Inhibitors Fluvoxamine
Other Gemfibrozil, Modafinil, Sulfasalazine, Methotrexate
a Antacids that directly neutralize stomach pH (i.e. Tums, Maalox) are permitted but may not be taken within 4 hours (before 
or after) study drug administration
bMay result in a decrease in the concentrations of study drug
c Use with study drug may result in an increase in the concentration of the HMG -CoA Reductase Inhibitors. The 28 day 
washout period does not apply to HMG-CoA Reductase inhibitors, which can be taken up to the day before Baseline/Day 1
Medications for disease conditions excludedfrom the protocol (eg, HIV -1, HBV, or HCV 
infection, active cancer, transplantation) are not listed under this prohibitedm edication section 
and are disallowed in the study .
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page40 29 June 20165.6. Accountability for GS -9674/ PTM GS-9674 
The investigator or designee (eg, p harmacist) is responsible for ensuring adequate accountability  
of all used and unused study  drug bottles. This includes acknowledgement of receipt of each 
shipment of study  drug (quantity  and condition), subject dispensing records, and returned or 
destroyed study product. All used and unused study  drug bottles dispensed to subjects must be 
returned to the site.
Study drug accountability  records will be provided to each study  site to:
Record the date received and quantity  of study drug bottles
Record the dat e, subject number, subject initials, and the study  drug bottle number dispensed
Record the date, quantity of used and unused study drug returned, along with the initials of 
the person recording the information.
5.6.1 I nvestigational M edicinal Product Return or Disposal
Refer to Section 9.1.7for instructions regarding study  drug return or disposal.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page41 29 June 20166. STUDY PROCEDURES
The study  procedures to be conducted for each subject randomized in the study  are presented in 
tabular form in Appendix 2and described in the text that follows. Additional information is 
provided in Study Reference Binder.
The investigator must document an y deviation from protocol procedures and notify  the sponsor 
or contract research organization (CRO).
6.1. Subject Randomization and Treatment Assignment
It is the responsibility  of the investigator to ensure that subjects are eligible to participate in the 
study prior to randomization and throughout the study . 
Documentation of the personally signed and dated informed consent of each subject, using the 
study-specific ICF, is required before initiating the screening process.
After written informed consent has been obtained and eligibility  to participate established, 
investigative site personnel will obtain the subject’s identification number and study  drug 
assignment from the interactive web response s ystem (IWRS).
6.2. Pretreatment Assessments -Screening Visit
Subjects will be screened within 4 weeksbefore randomization to determine eligibility  for 
participation in the study . The screening period may be extended under special circumstances 
with the explicit approval of the Medical Monitor. 
Screening labs may  be repeated once within the screening peri od, prior to administration of study  
drug to rule out laboratory error, if an y. This will be done at the discret ion of the investigator .
The following will be performed and documented at S creening:
Obtain written informed consent before initiation of an y screening procedure s
Review and record whether the subject meets inclusion and exclusion criteria
Obtain screening number from I WRS
Obtain medical history  
Calculate partial May o Score for subjects with IBD
Complete phy sical examination 
Record vital signs, body weight and height
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page42 29 June 2016Obtain blood samples for
Chemistry
Hematology  
Coagulation Panel
Biomarkers
HIV-1/2, HBV and HCV Serology
Serum pregnancy  test (female subjects of child bearing potential only)
Serum FSH (onl y for some female subjects -see Appendix 4) 
Cirrhosis assessment: FibroSURE/FibroTest®
Urine drug screen for amphetamines, cocaine and opiates (ie, heroin, morphine)
Record an y SAEsand all AEsrelated to protocol mandated procedures occurring after 
signing of the consent form.
Record all concomitant medications (CMs)thatthe subject has taken within 28 days prior to 
screening
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic withi n 4 weeks after screening for randomization into the study.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any AEsrelated to 
protocol-mandated procedures on the adverse events case re port form (eCRF).  All other 
untoward medical occurrences observed during the screening period, including exacerbation or 
changes in medical historyare to be captured on the medical history  eCRF.  See Section 7
Adverse Events and Toxicity  Management for additional details.
6.3.
Blinded Study Phase: Baseline/ Day 1 Randomization and Assessments
Subjects returning to the clinic for randomization at Baseline/Day 1 willbe instructed to fast (no 
food or drink, except wat er), starting from midnight or earlier, as appropriate, on the evening 
prior to the Baseline/Day 1 visit to ensure an approximate 8 -hour fast prior to the blood sample 
collection under fasting condition the next morning.
After review of inclusion and exclu sion criteria to confirm continued eligibility , subjects will be 
randomized to study  drug assignment and receive their Subject Identification Number via the 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. Final 
Original 
IWRS prior to their first dose of study drug. Randomization will be stratified by the presence or 
absence of UDCA use. 
The following will be performed and documented at the Baseline/Day 1 visit prior to dosing: 
• QoL Questionnaires (PBC-40, SF-36 and PSC PRO) 
• Pruritus assessments (Pruritus VAS and 5D-Itch) 
Note: It is recommended that QoL questionnaires be completed prior to any study procedures 
being performed and prior to the subject seeing a health care provider. Refer to the Study 
Reference Binder for guidance on QoL questionnaire administration. 
• Calculate partial Mayo Score for subjects with IBD 
• Symptom-driven physical examination 
• Record vital signs, weight and height 
• Obtain Blood samples for: 
Chemistry 
Hematology 
Coagulation Panel 
Lipid Profile 
C-peptide , insulin and hemoglobin Ale (HbAlc) 
Biomarkers 
Single PD Sampling 
• Conduct standard 12-Lead ECG 
• Perform FibroScan® (if available) 
• Collect urine samples for: 
Urine pregnancy test for females of child bearing potential only 
Biomarkers 
CONFIDENTIAL Page 43 29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page44 29 June 2016Collect stool sample 
Dispense study  drug, and provide subject with instruction on appropriate dosing and 
administration
Record all CMsthat the subject has taken since the previous visit
Record an y SAEsand all AEsoccurring since the Screening visit
Once all visit procedures have been completed, subjects will take their Baseline/Day  1 dose of 
study drug with food while at the investigative site
Subjects will return to the investigative site at Week 1 (±3 day s). 
6.4. Treatment Assessments (Blinded Study Phase)
6.4.1. Weeks 1, 2,4 and 8 (±3 days)
Subjects will be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to ensure an approximate 8 -hour fast prior 
to the fasted blood sample collection the next morning.
Subjects should also be instructed to HOLD their dose of study  drugon the day  of their visit until 
all visit procedures have been completed. The study  drug dose should be taken with food after 
the visit.
The following treatment procedures/assessm ents are to be completed at the end of Weeks 1, 2, 4, 
and 8 for all subjects (see Appendix 2).
Pruritus assessments ( Pruritus VAS and 5D-Itch)
Calculate partial May o Score for subjects with IBD
Symptom-driven phy sical examination
Record vital signs and body weight
Obtain blood samplesfor:
—Chemistry  
—Hematology  
—Coagulation Panel 
—Lipid Profile at Weeks 1 , 4and 8only
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
Biomarkers at Weeks 1 and 4 only 
Single PK and PD sampling 
• Obtain urine Samples for: Final 
Original 
Urine pregnancy testing (female of childbearing potential only) at Weeks 1, 4 and 8 only 
Biomarkers at Weeks 1 and 4 only 
• Dispense the study drug as directed by IWRS (if applicable) 
-Review study drug compliance and drug administration instructions with subject 
-Reconcile study drug administration using pill counts at Weeks 4 and 8 only 
• Record all CMs that the subject has taken since the previous visit 
• Record any SAEs and all AEs occurring since the previous visit 
6.4.2. Week 12 (± 3 days) 
Subjects will be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Week 12 visits to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning. 
The following treatment procedures /assessments are to be completed at this visit. 
• QoL Questionnaires (PBC-40, SF-36 and PSC PRO) 
• Pruritus assessments (Pruritus VAS and 5D-Itch) 
• Calculate partial Mayo Score for subjects with IBD 
• Symptom-driven physical examination 
• Record vital signs and body weight 
• Obtain blood samples for: 
-Chemistry 
CONFIDENTIAL Page 45 29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page46 29 June 2016Hematology
Coagulation Panel
Lipid Profile
C-peptide,insulin and hemoglobin A1c
Biomarker s
Single PK and PD sampling
Obtain Urine samplesfor:
—Urine pregnancy testing (female of childbearing potential only )
—Biomarker assessments
Collect stool sample 
Conduct standard 12 -Lead ECG
Perform FibroScan® (if available) 
Review study  drug compliance
—Reconcile stud y drug administration using pill counts
—All study drugsshould be returned at this visit
Record all CMsthat the subject has taken since the previous visit
Record an y SAEsand all AEsoccurring since the previous visit
Once all visit procedures have been completed, subjects will self -administer their last dose of 
study drug while at the investigative site. 
If a subject discontinues treatment earl y for any reason they should complete the 12 week 
treatment visit assessment/ Early  Termination Visit (ET) assessments then the follow up visit (4 
weeks following the last dose of the stud y drug) should be completed (see Appendix 2).
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page47 29 June 20166.5. Blinded Study Phasefollow-up Visit (±5 days)
Subjects will r eturn for a Blinded Study  Phase follow-up visit after completing their 12 weeks of 
treatment. The ET subjects should also complete the follow-u
p visit after completing the ET 
visit. 
The Blinded Stud y Phase follow-up visitwill be completed 4 week post last dose of study  drug.
The following will be performed and documented at this visit (see Appendix 2
).
QoL Questionnaires (PBC -40, SF-
36and PSC PRO ) 
Pruritus assessments (Pruritus VAS and 5D
-Itch)
Calculate partial May o Score for subjects with IBD
Symptom-driven phy sical examination
Record vital signs and body  weight
Obtain blood samples for:
—Chemistry
—Hematology
—Coagulation Panel
—Lipid Profile
—Biomarker s
Obtain Urine samples for:
—Urine pregnancy  testing (females of childbearing potential only )
—Biomarker s
Record all CMs that the subject has taken since the previous visit
Record an y SAEs and al l AEs occurring since the previous visit
Subjects will be unblinded to their Blinded Study  Phase treatment assignment after th e primary  
analysis has been completed, approximately  6 weeks after all subjects have completed the 
Blinded Study  Phaseor early terminated.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page48 29 June 2016Subjectsmust have their OLE Baseline/Day 1visitwithin 30 day s of completing the Blinded 
Study Phase follow -up. 
If OLE Baseline/Day  1 and Blinded S tudy Phase follow -up visitis on the same day  subjects 
should only  complete OLE Baseline /Day  1 assessments.
6.6. Open Label Extension (OLE) Phase (±5 days)
Subjects will be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to their visits to ensure an approximate 8 -
hour fast prior to the fasted blood sample collection the nex t morning.
Subjects should also be instructed to HOLD their dose of study  drugon the day  of the 
Baseline/Day  1 visit until all visit procedures have been completed. The study drug dose should 
be taken with food after the visit.
The following treatment procedures/assessme nts are to be completed at the OLEBaseline/Day  1
Visit, followed by  OLEWeeks4, 12, 24, 36, 48, 60, 72, 84 and 96 weeks (see Appendix 2).
QoL Questionnaires (PBC -40, SF-36and PSC PRO ) 
Pruritus assessments (Pruritus VAS and 5D
-Itch)
Calculate partial Mayo Score for subjects with IBD
Symptom-driven physical examination
Record vital signs and body  weight
Obtain blood samples for
Chemistry
Hematology
Coagulation Panel
Lipid Profile
Biomarker s
Obtain Urine samples for:
—Urine pregnancy testing (females of childbearing potential only )
—Biomarker sat OLE Baseline/Day  1, Weeks 24, 48, 72 and 96 only
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page49 29 June 2016Collect stool sample atOLE Baseline/Day  1, Week 48 and W eek 96only
Dispense the stud y drug as directed b y IWRS
Review study  drug compliance and drug administrati on instructions with subject
—Reconcile stud y drug administration using pill counts
—Study drug should be returned at Week 96 visit
Record all CMsthat the subject has taken since the previous visit
Record an y SAEsand all AEsoccurring since the previous visit
6.7. Unscheduled Visit s
Additional unscheduled assessments may be performed at the discretion of the investigator.
Subjects returning to the clinic for an unscheduled visit willbe instructed to fast (no food or 
drink, except water), starting from midnight (00:00) or earlier, as appropriate, on the evening 
prior to the visit to ensure an approximate 8 -hour fast prior to the blood sample collection under 
fasting condition the next morning.
Subjects should also be instructed to HOLD their dose of study  drugon the day  of an 
unscheduled visit until all visit procedures have been completed. The stud y drug dose should be 
taken with food after the visit.
At a minimum, the following will be performed and documented.
Calculate partial Mayo Score for subjects with IBD
Symptom-driven phy sical examination
Obtain blood samples for:
—Chemistry
—Hematology
—Single PK and PD should be collected for an y unscheduled visit during Blinded Study  
Phase (Weeks 1to 12visits).
Record bod y weight
Record all CMsthat the subject has taken since the previous visit
Record an y SAEsand all AEsoccurring since the previous visit
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page50 29 June 20166.8. OLE follow-up Visit(±5 days)
Subjects will return for OLE follow-up visit after completing their OLEWeek 96visit. Subjects 
should also complete the follow-up visit after completing the ET visit for the OLE Phase. 
The OLE follow-
up visit will be completed 4 week post 
last dose of study  drug.
The following will be performed and documented at this visit (see Appendix 2).
Pruritus assessments ( Pruritus VAS and 5D-Itch)
Calculate partial May o Score for subjects with IBD
Symptom-driven phy sical examination
Record vital signs and body  weight
Obtain blood samples for:
—Chemistry
—Hematology
—Coagulation Panel
—Lipid Profile
Urine pregnancy  test for female subjects of child bearing potential onl y 
Record all CMsthat the subject has taken since the previous visit
Record an y SAEsand all AEs occurring since the previous visit
6.9. Assessments for Premature Discontinuation from Study
Subjects prematurel y discontinuing from the study either during the B
linded Study Phase or 
during the OLE Phase (for example, as a result of an AE), should have an Earl y Termination 
(ET) visit completed followed b y afollow-upvisit 4 weeks after the last dose of the study  
medication . The stud y assessments to be performed at the ET visit are the same as those 
performed at the Week 12 visit (refer to Section6.4.2)for ET subjects in the B
linded Study  
Phase and Week 96 visit for ET subjects in the OLE Phase(refer to Section 6.6).The study 
assessments to be performed at the follow-up visitsare listed in Section6.5and 6.8respectivel y
. 
The subject will then be withdrawn from the study .
If these visits are not possible or acceptable to the subject or investigator, the subject may  be 
withdrawn from the study. 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
6.10. Criteria for Discontinuation of Study Treatment 
Study medication may be discontinued in the following instances: Final 
Original 
• Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness, the subject 
may resume study dosing at the discretion of the investigator. 
• Unacceptable toxicity, or toxicity that, in the judgment of the investigator, compromises the 
ability to continue study-specific procedures or is considered to not be in the subject's best 
interest 
• Subject request to discontinue for any reason 
• Subject noncompliance 
• Pregnancy during the study; refer to Appendix 4. 
• Sponsor discretion 
• Discontinuation ofthe study at the request of Gilead, a regulatory agency or an institutional 
review board or independent ethics committee (IRB /IEC) 
6.11. PK and PD Substudy Visits 
6.12. Procedures and Specifications 
6.12.1. Clinical Laboratory Analytes 
Chemistry: 
Alanine aminotransferase ( AL T), aspartate aminotransferase (AS T), albumin, alkaline 
phosphatase (ALP), bicarbonate, blood urea nitrogen (BUN), calcium, chloride, creatinine, 
glucose, lactate dehydrogenase (LDH), magnesium, phosphorus, potassium, sodium, total and 
CONFIDENTIAL Page 51 29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page52 29 June 2016direct bilirubin, total protein, uric acid, gamma- glutamyl transferase (GGT). Also includes 
C-Peptide, insulin and hemoglobin A1c (HbA1c) for the Baseline/Day 1and Week 12 visits.
Creatinine clearance is calculated b y the Cockcroft -Gault equation {Cockcroft et al 1976 }using 
actual bod y weight (BW). The calculation will b e performed b y the central laboratory .
Hematology :
Hematocrit (Hct), hemoglobin (Hb), platelet count, red blood cell count (RBC), white blood cell 
count (WBC) with differential (absolute and percentage) including lymphocytes, monocytes, 
neutrophils, e osinophils, and 
basophils and, reticulocy te count and mean corpuscular volume 
(MCV).
Coagulation Panel:
Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio 
(INR)
Pregnancy  Tests:
Serum β-hCG or urine β -hCG (if positive, requires immediate confirmation with Serum β- hCG)
Additional Tests:
Lipid Profile, HI V-1, HBV & HCV Serology , urine drug screen (for amphetamines, cocaine, 
opiates), and genomic sample collection
Biomarker tests
Including but not limited to biomarke rs of:
Circulating lipids -ApoB and NMR lipoprofile
Inflammation - hsCRP, TNF -α 
Bone formation – bone specific ALPand PTH
Liver fibrosis –ELF Test and FibroSURE/FibroTest®
FXR pathway  activity -FGF19, C4and bileacids
Urine samples :
Collected and stored for future biomarker testing(protein, albumin, retinol binding protein, β 2-
microglobulin and creatinine)
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
Pharmacokinetic (PK) and Pharmacodynamic (PD) Assessments 
Single PK and PD Sampling Final 
Original 
Single PK and PD plasma samples will be collected and archived for 1) PK analysis of GS-9674, 
GS-716070 (metabolite of GS-9674 ), and other metabolites as applicable , 2) to measure the 
concentration ofthe PD biomarkers FGF19 and C4. 
6.12.2. Medical History 
Medical history including details regarding illnesses and allergies, date(s) of onset, and whether 
condition(s) is currently ongoing, and medication history, including nicotine and alcohol use, 
will be collected on all subjects during screening. 
6.12.3. Physical Examination 
A complete physical examination should include source documentation of general appearance, 
and the following body systems: head, neck, and thyroid; eyes, ears, nose, throat, mouth, and 
tongue; chest (excluding breasts); respiratory; cardiovascular; lymph nodes; abdomen; skin, hair, 
nails; musculoskeletal and neurological. 
The focus of a symptom-driven physical examination will be determined by the investigator 
based on subject complaint. For example if a subject complains of a cough a respiratory exam 
should be performed. If consistent with pneumonia (e. g. rales or crackles are identified) then an 
AE would be documented. 
Height and body weight will be collected at specified time points. 
6.12.4. Quality of Life (QoL) Measures and Pruritus Assessments 
It is recommended that these questionnaires be completed prior to the clinical and laboratory 
assessments. The subject should read the questionnaires by himself/herself and record the 
answers by himself/herself. 
6.12.4.1. Short Form-36 (SF-36) Health Survey 
The SF-36 Health Survey asks 36 questions to measure functional health and well-being from the 
subject's point of view and consists of eight health domains (physical functioning, role-physical, 
bodily pain, general health, vitality, social functioning, role-emotional, and mental health). These 
health domain scales contribute to the physical health and mental health summary measures. 
CONFIDENTIAL Page 53 29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page54 29 June 20166.12.4.2. Partial May o Score
The partial May o score is a survey  for the assessment of IBD that considers stool frequency , 
rectal bleeding, and a physician’s global assessment of disease severity .
6.12.4.3. PSC Patient -Reported Outcome (PRO) Measure
The PSC PRO addresses the severit y of common, everyday s ymptoms of PSC (e.g. pruritus, 
fatigue, right upper quadrant abdominal discomfort) and their functional im pact (e.g. on ph ysical 
function, activities of daily  living, work productivity , etc.). 
6.12.4.4. Primary Biliary Cirrhosis -40 (PBC-40) Questionnaire
The PBC-40 is a health -related Qo L questionnaire that includes 40 questions regarding PBC -
related symptoms including itch, fatigue, cognition, and social and emotional assessments
symptoms that are also relevant to the PSC population .  
6.12.4.5. Pruritus V isual Analog Scale (VAS) measure
The Pruritus VAS is a toolthat uses a numeric scale for measuring the intensity  of pruritus.
6.12.4.6. 5D-I tch Questionnaire
The 5D-Itch questionnaire is a validated survey  for the assessment of the severit y of pruritus in 
patients with chronic pruritus due to dermatological and non- dermatological disorders. 
6.12.5. Electrocardiogram
Standard 12-lead electrocardiogram (ECG) assessments will be performed. The Investigator will 
review the ECGs for an y clinically significant abnormalities to ensure subject safety . Abnormal 
ECG findings that are considered clinicall y significant by the Investigator and meet the 
definition of an AE should be reported and recorded in the AE eCRF page.
6.12.6. FibroScan® 
Liver stiffness will be assessed b y FibroScan®. It is required that each subject’s FibroScan®
assessments be done with the same ty pe of probe at each study  visit. If FibroScan® is not 
available at a site the test may  be omitted.
Please refer to the Stud y Reference Binder for instructions on FibroScan®measurements.
6.13. End of Study
End of study  is defined as when the last patient last visit (L PLV) for the OLE follow-up visit 
occurs 4 weeks after completing OLE treatment ortheOLE ET follow -up visit, whichever 
occurs later.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page55 29 June 20166.13.1. Sample Storage
Residual biological samples from all visits will be frozen and s tored. These stored samples may  
be used b y Gilead or our research partners to help answer questions about the study drug, PSC 
and its associated conditions, or clinical laboratory  testing to provide additional safet y data. No 
human genetic testing will be performed without express consent of the study  subjects. At the 
conclusion of this study , these samples may  be retained in storage for Gilead for a period of up to 
15 years.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page56 29 June 20167. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reac tions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study subject 
administered a medicinal product,which does not necessarily  have a causal relationship with th e
treatment. An AE can ther efore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, overdose, drug abuse/misuse reports , or occupational 
exposure. Preexisting events that increase in severity  or change in nature during or as a 
consequence of participation in the clini cal study will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such assurgery, endoscopy , tooth extraction, andtransfusion.
T
he condition that led to the procedure may be an adverse event and must be reported
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
Screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (e g., hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Section7.6.1)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. It is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life-threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospital ization or prolongation of existing hospitalization
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page57 29 June 2016Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospita lization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules . Examples of medically  important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to study drug interruption , modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1and 7.1.2.If the laboratory  
abnormality
 is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to (Section7.5
).
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator i s responsible for assessing AEs and SAEs for 
causality and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigato r is responsible for assessing the relationship to 
GS-9674 
therapy using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the GS -9674
. For 
SAEs, an alternative causality  must be provi ded (eg, pre -existing condition, underly ing 
disease, intercurrent illness, or concomitant medication).
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page58 29 June 2016Yes:There is reasonable possibility  that the event may  have been caused by the 
investigational medicinal product.
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed usi ng the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes:The adverse event occurred as a result of protocol procedures (eg.,venipuncture)
7.2.2. Assessment of Severity
The severit y grading of AEs will be assessed as Grade 1, 2, 3, 4or 5according to the 
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, which can be found 
at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_ 8.5x11.pdf
(Appendix 3).
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory  abnormality .
The distinction between the seriousness and the severity of an adverse event should be noted. 
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For 
example, a headache may be severe in intensity , but would not be classified a s serious unless it 
met one of the criteria for serious events listed above.
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be report ed on the case report form ( eCRF): all SAEs and adverse events related to 
protocol-mandated procedures.
Adverse Events
Following initiation of stud y medication, collect a ll AEs, regardless of cause or relationship, 
until 30 days after last administration of GS-
9674; AEs must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is st able, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page59 29 June 2016Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in t he study (ie, signing the informed consent) and throughout the duration of the 
study, including the protocol -required post treatment follow-up period, must be reported to the 
eCRF database and Gilead Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit and within 30 days of 
the last dose of study  drug, regardless of causa lity, should also be reported. 
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period; 
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly  document and report 
the event to Gilead DSPH.
All AEs and SAEs will be recorded in the eCRF database within th e timelines outlined in the 
eCRF completion guideline. 
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for any reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning, record t he SAE on the paper serious adv erse event reporting 
form and submit within 24 hours to:
Gilead DSPHEmail: Safety_FC@gilead.com
Fax: +1 650-522-5477
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
For fatal or life -threatening events, copies of hospital case reports, autops y reports, and other 
documents are also to be submitted by  e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
Additional information may  be requested to ensure the timely  completion of accurate safet y 
reports.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page60 29 June 2016Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form.
7.4. Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, Gilead may be required to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). I n accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulatory  
agencies and the relevant I EC in concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by  Gilead using reference safety  
information specified in the investigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with any study drug. The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy .
To minimize the possibility  of exposing stud y subjects to unusual risk, the safet y information 
from this study  will also be reviewed periodicall y by an independent Data Monitoring 
Committee (DMC). The DMC may  have access to partially  blinded or unblinded data and will 
make recommendations regarding the stud y according to the DMC charter. See Section8.12for
additional details regarding the DMC.
7.5. Toxicity Managem ent 
7.5.1. PSC Specific Study Stopping Rule:
Any subject without a history  of IBD,who develops new onset IBD while participating in the 
study, must be discontinued from the stud y.Any subject with a history  of IBDwho experiences 
at least a 3 -point increase in the partial Mayo score while in the study  must be discontinued from 
the study.
7.5.2. Observation for Drug Induced Liver Injury (DILI):
Although subjects randomized in this study  will have baseline liver disease, their hepatic 
function should not be significantly  impaired. However, at baseline, some may  haveliver 
biochemistry  levelsabove the upper limit of normal (ULN). 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page61 29 June 2016For subjects with ALT and AST below ULN at study start, close observation for DILI (as 
described below) should be considered in subjects with any of the following criteria (all labs 
confirmed b y repeat testing):
ALT or AST > 3 x ULN 
Total bilirubin > 2 x ULN
Alkaline phosphatase > 3 x ULN
INR >1.5 x ULN (except for subjects on anticoagulant therapy )  
Clinical signs or symptoms that are, in the opinion of the investigator, consistent with 
hepatitis (such as right upper quadrant discomfort, fever, nausea, vomiting, jaundice, rash, or 
eosinophilia > 5%)
For subjects with ALT or AST between 1 and 5 x ULN at study  start, close observation for DILI 
(as described below) should be considered in subjects with an y of the following criteria (all labs 
confirmed b y repeat testing):
ALT or AST > 2 x baseline at an y time
Total bilirubin > 2 x ULN  
Alkaline phosphatase > 3 x ULN
INR >1.5 x UL N (except for subjects on anticoagulant therapy )  
Clinical signs or symptoms that are, in the opinion of the investigator, consistent with 
hepatitis (such as right upper quad rant discomfort, fever, nausea, vomiting, jaundice, rash, or 
eosinophilia > 5%).  
Close observation includes:
Repeating liver biochemistries (ALT, AST, ALP, total bilirubin, I NR) within 48 hours
Obtaining a more detailed history  of symptoms and prior or c oncurrent disease
Obtaining a history  of concomitant drug use (including nonprescription medications and 
herbal and dietary  supplement preparations), alcohol use, recreational drug use, and special 
diets
Obtaining a history  of exposure to environmental chemical agents
Ruling out other causes of liver disease as needed (obtain viral hepatitis panel, imaging for 
evaluation of biliary  tract disease, etc. if required in the opinion of the primary  investigator)
Continue to monitor liver biochemistries twice week ly. Frequency  can decrease to once a 
week or less if abnormalities stabilize or study  drug has been discontinued and subject is 
asymptomatic
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page62 29 June 2016During a period of close observation, study  drug can be continued, if desired, at the discretion of 
the Gilead Medical Monitor and the principal investigator during the DILI evaluation. 
However, for all subjects, study drug should be withheld if any  of the following criteria are met:
ALT or AST > 3 x ULN AND either Total bilirubin > 2 x UL N or INR > 1.5 (in subjects not 
on anticoagulation)
ALT or AST > 3 x ULN AND the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
ALT or AST > 8 x ULN 
ALT or AST >5 x ULN for more than 2 weeks
AND
No other cause for the combination of laboratory  abnormalities is immediately  apparent (e.g. 
prolonged INR with warfarin use) i mportant potential causes or contributors to abnormal 
AST/ALT or total bilirubin values include, but are not limited to:
—Obstructive gall bladd er or bile duct disease
—Viral or alcoholic hepatitis (e.g. hepatitis A/B/C/D/E, Epstein -Barr virus, 
cytomegalovirus, herpes simplex virus, varicella)
—Autoimmune hepatitis
— Concomitant administration of other hepatotoxins, including excessive doses of 
acetaminophen, drugs that inhibit bilirubin glucuronidation (e.g. indinavir, atazanavir, 
irinotecan), or herbal or dietary  supplements
—Hypoxic or ischemic hepatopathy  or congestive hepatopathy  in association with 
significant right -sided heart failure
—Wilson dise ase
—Nonalcoholic fatty liver disease (NAFLD)
—
Progression of malignancy involving the liver (note that metastatic disease to the liver, by  
itself, should not be used as an explanation for significant AST/ALT elevations)
Treatment -emergent toxicities will be noted by the Investigator and brought to the attention of 
the Medical Monitor. Whether or not considered treatment -related, all subjects experiencing AEs 
must be monitored periodically  until symptoms subside, any  abnormal laboratory  values have 
resolved or returned to baseline levels or they are considered irreversible, or until there is a 
satisfactory  explanation for the changes observed.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page63 29 June 2016Other than in the case of the liver enzy mes noted above, Grade 3 or 4 clinically  significant 
laboratory  AEs should be confirmed b y repeat testing as soon as practical to do so, and 
preferably within 3 calendar day s of receipt of the original test results.
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of 
the clinical severit y in the context of the underl ying conditions; this may  or may not be in 
agreement with the grading of the laboratory  abnormality .
Any questions regarding toxicity  management should be directed to the Medical Monitor.
7.6. Special Situations Reports
7.6.1. Definitions of S pecial Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose, reports 
of AEs associated with product complaints, occupational exposure with an AE, pregnancy  
reports regardless of an associated AE, and AE in an infant following exposure from 
breastfeeding .  
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer. 
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional andinappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing in formation.
An overdose is defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per p rotocol or in the product labeling (as it app lies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot a ccount for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
Occupational exposure with an AE: exposure to a medicinal product as a result of one’s 
professional or non- professional occupation.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page64 29 June 20167.6.2. Instructions f or Reporting Special Situations
7.6.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study medication and throughout the study , including the post study drug follow -up 
period, to Gilead DSPH using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy .
Refer to 
Section7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is alway s considered to be an SAE and w ill be reported as described in 
Sections7.1.1and7.1.2.Furthermore, an y SAE occurring as an adverse pregnancy  outcome post 
studymust be reported to Gilead DSPH .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to Gilead DSPH using the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been completed, the outcome should 
be reported directl y to Gilead DSPH. Gilead DSPH contact information is as follows: Email: 
Safety_FC@gilead.com and Fax: +1 (650 ) 522-5477. 
Pregnancies of female partners of male stud y subjects exposed to Gilead or other study  drugs 
must also be reported and relevant information should be submitted to Gilead DSPH using the 
pregnancy  and pregnancy  outcome forms within 24 hours. Mon itoring of the subject should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study  
has been completed, the outcome should be reported directl y to Gilead DSPH, fax number +1 
650 522-5477 or email Safet y_FC@gilea d.com. 
Refer to Appendix 4forPregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements
.
7.6.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that invo lve study drugand/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications. 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page65 29 June 2016Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a non
-
Gilead concomitant medication , theAE should be reported on the AE form . 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to Section 7.3and the eCRF com pletion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. D etails of the sy mptoms and 
signs, clinical management, and outcome will be reported , when available.
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
8. STATISTICAL CONSIDERATIONS 
Details will be provided in the Statistical Analysis Plan (SAP). 
8.1. Analysis Objectives and Endpoints 
8.1.1. Analysis Objectives 
The primary objective of this study is: 
• To evaluate the safety and tolerability of GS-9674 in subjects with PSC 
The exploratory objectives ofthis study are: 
IT 
I 
I 
I 
I 
I 
I 
I I 
I 
8.1.2. P1imary Endpoint -Final 
Original 
The primary endpoint is the safety of GS-9674 in subjects with PSC without cirrhosis. The safety 
and tolerability of GS-9674 will be evaluated by examining the incidence of treatment-emergent 
adverse events, including serious adverse events, clinical laboratory tests, and vital signs 
assessments at various time points during the study. 
CONFIDENTIAL Page 66 29 June 2016 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
8.1.3. 
I 
I -I 
I -I 
I 
I 
I 
I 
I 
I 
I 
I 
8.2. 
8.2.1. 
8.2.1.1. Exploratory Endpoints 
Analysis Conventions 
Analysis Sets 
Efficacy Final 
Original 
The primary analysis set for efficacy analysis will be the Full Analysis Set (F AS) which includes 
all subjects who were randomized into the study and received at least one dose of study drug. 
CONFIDENTIAL Page 67 29 June 2016 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. Final 
Original 
Subjects who receive study drug other than that to which they were assigned will be analyzed 
according to the treatment group to which they were randomized. 
8.2.1.2. Safety 
The primary analysis set for safety analyses will include all subjects who received at least one 
dose of study drug. Treatment-emergent data will be analyzed and defined as data collected from 
the first dose of study drug through the date of last dose of study drug plus 30 days. Subjects 
who received study drug other than that to which they were assigned will be analyzed according 
to the study drug received. 
8.2.1.3. Pharmacokinetics 
There are two pharmacokinetic analysis sets: 1) the PK analysis set which includes 
concentration data from the s · drawn at each visit 
The PK analysis set will include all randomized subjects who took at least one dose of study 
drug and for whom concentration data of analytes GS-9674 (and its metabolites as applicable) 
are available. The PK analysis set will be used for analyses of population PK. 
PPD 
8.2.1.4. Pharmacodynamics 
There are two pharmacodynamics analysis sets: 1) The PD is set which includes 
concentration data from the s · drawn at each visit 
The PD analysis set will include all randomized subjects who took at least one dose of study 
drug and for whom concentration data ofFGF19, C4, and bile acids are available. The PD 
analysis set may be used for descriptive and/or population based PD analyses as applicable. 
PPD 
CONFIDENTIAL Page 68 29 June 2016 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
8.2.1.5. Biomarkers Final 
Original 
The Biomarker Analysis Set will include data from subjects in the Safety Analysis Set who have 
the necessary baseline and on-study measurements to provide interpretable results for the 
specific parameters of interest. 
8.2.2. Analysis by Study Phase 
Result of statistical analysis for the randomized phase will be presented by treatment groups. 
Safety data from the OLE Phase will be summarized for overall subjects who roll-over into the 
OLE Phase for safety review, supporting regulatory document update or publication purposes. 
An administrative interim analysis will be performed after first 30 subjects finish 12 weeks of 
treatment. 
8.3. Data Handling Conventions 
Missing data can have an impact on the interpretation of the trial data. In general, values for 
missing data will not be imputed. 
Where appropriate, safety data for subjects that did not complete the study will be included in 
summary statistics. For example, if a subject received study medication, the subject will be 
included in a summary of adverse events according to the treatment received; otherwise, if the 
subject is not dosed then they will be excluded from the summary. If safety laboratory results for 
a subject are missing for any reason at a time point, the subject will be excluded from the 
calculation of summary statistics for that time point. If the subject is missing a pre-dose value, 
then the subject will be excluded from the calculation of summary statistics for the pre-dose 
value and the change from pre-dose values. 
Values for missing safety laboratory data and vital signs will not be imputed; however, a missing 
baseline result will be replaced with a screening result, if available. If no pre-treatment 
laboratory value is available, the baseline value will be assumed to be normal (ie, no grade 
[Grade 0]) for the summary of graded laboratory abnormalities. 
8.4. Demographic Data and Baseline Characteristics 
Demographic and baseline measurements will be summarized using standard descriptive 
methods (n, mean, SD, median, Ql, Q3, minimum, and maximum) by treatment group and 
overall. Demographic summaries will include sex, race/ethnicity, and age. 
Baseline characteristics summary will include body weight, height, body mass index, and other 
disease characteristics. 
8.5. Efficacy Analysis 
CONFIDENTIAL Page 69 29 June 2016 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
PPD 
8.6. Exploratory Analyses 
PPD 
8.7. Safety Analysis Final 
Original 
All safety data collected on or after the date that GS-9674 was first dispensed up to the date of 
last dose of GS-9674 plus 30 days will be summarized by treatment group. Data for the 
pretreatment and follow-up periods will be included in data listings. 
8.7.1. Extent of Exposure 
Data for a subject's extent of exposure to GS-9674 will be generated from the study drug 
administration eCRF. Exposure data will be summarized by treatment group. 
8.7.2. Adverse Events 
Clinical and laboratory adverse events will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA). System Organ Class (SOC), High-Level Group Term 
(HLGT), High-Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be 
attached to the clinical database. Adverse event severity will be graded using the CTCAE 
Version 4. 03. 
Events will be summarized on the basis of the date of onset for the event. Treatment-emergent 
adverse events (TEAEs) are defined as 1 or both ofthe following: 
• Any AEs with an onset date on or after the study drug start date and no later than 30 days 
after permanent discontinuation of study drug 
• Any AEs leading to premature discontinuation of study drug 
Summaries (number and percentage of subjects) of TEAEs by SOC and PT will be provided. 
Treatment-emergent AEs will also be summarized by relationship to study drug and severity. In 
addition, TEAEs leading to premature discontinuation of study drug and study will be 
summarized and listed. 
All AEs collected during the course of the study will be presented in data listings with a field for 
treatment-emergent event (yes/no). 
CONFIDENTIAL Page 70 29 June 2016 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
8.7.3. Laboratory Evaluations Final 
Original 
Selected laboratory data will be summarized (n, mean, SD, Median, Q1, Q3, minimum, and 
maximum) by treatment group and study visit along with the corresponding change from 
baseline values. 
Graded laboratory abnormalities will be defined using the grading scheme in the CTCAE 
Version 4.03 (Appendix 3). Grading oflaboratory abnormalities for analysis purposes will be 
performed by the central laboratory. 
Incidence of treatment-emergent laboratory abnormalities, defined as values that increase at least 
1 toxicity grade from baseline at any time post baseline up to and including the date of last dose 
of study drug plus 30 days will be summarized by treatment group. If baseline data are missing, 
then any graded abnormality (ie, at least a Grade 1) will be considered treatment emergent. 
8.7.4. Other Safety Evaluations 
Vital sign measurements and 12-lead ECG data will be summarized by treatment group and 
listed by subject. 
8.8. Phannacokinetic Analysis 
Plasma concentrations and pharmacokinetic parameters (eg, AUCtau, Cmax and Ctau) will be 
listed and summarized as appropriate for GS-967 4 (and its metabolites as applicable) using 
descriptive statistics. 
Details ofthe analysis plan will be provided in the pharmacokinetic reporting and analysis plan. 
8.9. Pharmacodynamics Analysis 
Primary PD parameters (AUCpartiai, Cmax, Cmin as applicable) ofFGF19 and C4 will be listed and 
summarized as appropriate for GS-9674 using descriptive statistics. 
Details ofthe analysis plan will be provided in the pharmacodynamics reporting and analysis 
plan. 
8.10. Biomarker Analysis 
Descriptive statistics of biomarker expression and change from baseline will be provided at each 
sampling time by treatment. Point estimates and 95% confidence intervals may be calculated. 
PO 
PPD 
CONFIDENTIAL Page 71 29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page72 29 June 20168.11. Sample Size
Due to the exploratory  nature of this study , no formal power calculations were used to determine 
sample size. The number of subjects was chosen based on clinical experience with other similar 
proof of concept studies.
8.12. Data Monitoring Committee
An independent, external data monitoring committee (DMC) that consists of two hepatologists 
and a PhD statistician will review the progress of the study  and perform reviews of safety  data. 
The DMC will convene once 20 subjects have been randomized and willmeet every  3 to 4 
months thereafter to monitor the study  for safety eventsin Blinded Study  Phase and every  6 
month in the OL E Phase.The DMC will meet on an ad hoc basis if there are at least 3similar 
Grade ≥ 3 serious, treatment related Common Terminology Criteria for Adverse Events 
(CTCAE) observed in the trial. In the event of two similar treatment -related Grade 4CTCAE 
events or one treatment -relatedGrade 5CTCAE, the DMC will review the data and advise the 
sponsor regarding stopping or continuing the trial. The DMC will provide recommendation to 
Gilead whether the nature, frequency , and severity  of adverse effects associated with study  
treatment warrant the early termination of the study  in the best interests of the participants, 
whether the stud y should continue as planned, or the study  should continue with modifications. 
The DMC may  also provide recommendations as needed regarding stud y design.
The DMC’s specific activities will be defined b y a mutually  agreed charter, which will define the 
DMC’s membership, conduct and meeting schedule.
While the DMC will be asked to advise Gilead regarding future conduct of the study , including 
possible earl y study termination, Gilead retains final decision -making authority  on all aspects of 
the study.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page73 29 June 20169. RESPONSIBIL ITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki, International Conference on Harmonisation (ICH) guidelines, or with 
the laws and regulations of the country  in which the research is conducted, whichever affords the 
greater protection to the study  subject. These standards are consistent with the European Union 
Clinical Trials Directive 2001/20/EC and Good Clinical Practice Dir ective 2005/28/EC .
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply  with 21CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary  
interests in the investigational drug under stud y. This documentation must be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of an y change in reportable interests during the stud y and 
for 1 year following completion of th e study. Study completion is defined as the date when the 
last subject completes the protocol- defined activities.
9.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to a n IRB/IEC/EC. The investigator will not begin an y study subject activities 
until approval from the IRB/IEC/EChas been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approva l from 
the IRB/IEC/ECany modifications made to the protocol or an y accompan ying material to be 
provided to the subject after initial IRB/IEC/ECapproval, with the exception of those necessary 
to reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y study-related procedures. The 
investigator must use the most current IRB/IEC/EC-approved consent form for documenting 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page74 29 June 2016written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legall yauthorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required by  IRB/IEC/EC
local requirements.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB/IEC/EC,or laboratory . Laboratory  
specimens must be labeled in such a way as to protect subject identity  while allowing the results 
to be recorded to the proper subject . NOTE: The investigator must keep a screening log showing 
codes, names, and addresses for all subjects screened and for all subjects randomized in the trial.
Subject data will be processed in accordance with all applicable regulations. 
The investigator agrees t hat all information received from Gilead, including but not limited to the 
investigator b
rochure, this protocol, eCRF , the study  drug, and any other study  information, 
remain the sole and exclusive propert y of Gilead during the conduct of the study and the reafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reas onable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study  file, and 
(2)subject clinical source documents.
The inves tigator’s study  file will contain the protocol/amendments, CRF and query  forms
IRB/IECand governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and corres pondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not randomized;
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page75 29 June 2016Participation in study (including study number);
Study discussed and date of informed c onsent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of study drug, including dates of dispensing and 
return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality and severity);
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study completion and reason for earl y discontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe , or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified 
by regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y away fromthe site so that they  can be returned sealed to the investigator 
in case of a n inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away fromthe site.
9.1.6. Case Report Forms
For each subject consented, an electronic case report form ( eCRF)will becompleted b y an 
authorized study  staff member whose training for this function is documented according to study  
procedures. eCRFshould be completed on the day of the subject visit to enable the sponsor to 
perform central monitoring of safet y data.  The Eligibility  Criteria eCRF should be completed 
only after all data related to eligibility  have been received.  Subsequent to data entry , a study 
monitor will perform source data verification within the EDC sy stem.Original entries as well as 
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page76 29 June 2016any changes to data fields will be stored in the audit trail of the sy stem.  Prior to database lock 
(or any interim time points as described in the clinical data management plan), the investigator 
will use his/her log in credentials to confirm that the forms have been re viewed, and that the 
entries accurately  reflect the information in the source documents. The eCRF capture the data 
required per the protocol schedule of events and procedures. System-generated or manual 
queries will be issued to the investigative site st aff as data discrepancies are identified by  the 
monitor or internal Gilead staff, who routinel y review the data for completeness, correctness, and 
consistency . The site coordinator is responsible for responding to the queries in a timely  manner, 
within the system, either by  confirming the data as correct or updating the original entry , and 
providing the reason for the update (e.g. data entry error). At the conclusion of the trial, Gilead 
will provide the site with a read -only archive cop y of the data ente red by that site. This archive 
must be stored in accordance with the records retention requirements outlined in Section9.1.5.
9.1.7. Investigational Medicinal Product Accountability and Return
Where possible, study  drug should be destroy ed at the site. If the s ite does not have acceptable 
procedures in place for drug destruction, arrangements will be made between the site and 
GileadSciences (or Gilead Sciences’ representative) for return of unused study  drug supplies. 
The study  monitor will provide instructions for return.
The study  monitor will evaluate each study  center’s study  drug disposal procedures and provide 
appropriate instruction for destruction of unused study drug supplies. If the site has an 
appropriate standard operating procedure (SOP) for drug de struction as determined by  Gilead 
QA, the site may  destroy used (empt y or partially empty) and unused stud y drug supplies in 
accordance with that site’s approved SOP. A cop y of the site’s approved SOP will be obtained 
for central files. 
If study drug is d estroyed on site, the investigator must maintain accurate records for all study  
drug destro yed. Records must show the identification and quantity of each unit destroyed, the 
method of destruction, and the person who disposed of the study  drug. Upon study  completion, 
copies of the stud y drug accountability records must be filed at the site. Another cop y will be 
returned to Gilead. Refer to the pharmacy  binder for study  drug disposal/return instructions.
The study  monitor will review study  drug supplies and a ssociated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all
source documents and other records for this trial to 
Gilead’s appointed stud y monitors totheIRB/IEC/EC, or to regulatory  authority  or health 
authority inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page77 29 June 20169.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit a ll protocol modifications to the IRB/IECin 
accordance with local requirements and receive documented IRB/IEC/ECapproval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agenc ies.Gilead 
will ensure that the report meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases.
Investigators in this study  may communicate, orally  present, or publish in scientific journals or 
other scholarl y media only a fter the following conditions have been met: the results of the stud y 
in their entiret y have been publicly disclosed b y or with the consent of Gilead in an abstract, 
manuscript, or presentation form or the stud y has been completed at all study sites for at least 2 
years.
The investigator will submit to Gilead any  proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 day s before submission of the 
publication or presentation. 
No such communication , presentation, or publication will include Gilead’s confidential 
information (see Section9.1.4).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presen tation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I nvestigator's Meetings.  If required under the applicable statutory  
and regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbur sed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page78 29 June 20169.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor m ust have direct access to the 
investigator’s source documentation in order to verify  the accuracy of the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study to verify adherence to t he protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected through any  type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study. If t he investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory authorities, IRBs/ IECs/ECs. In terminating the study , Gilead and the investigator will 
assure that adequate consideration is given to the protection of the subjects’ interests.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page79 29 June 201610. REFERENCES
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Graziadei I W, Wiesner RH, Marotta PJ, Poray ko MK, Hay  JE, Charlton MR, et al. L ong-term 
results of patients undergoing liver transplantation for prima ry sclerosing 
cholangitis. Hepatology  1999;30 (5):1121-7.
Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL , McDonald JG, et al. Fibroblast growth 
factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. 
Cell metabolism 2005;2 (4) :217-25.
Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, et al. Genome -wide association 
analysis in primary  sclerosing cholangitis. Gastroenterology  2010;138 (3):1102-
11.
Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in p atients with primary  
sclerosing cholangitis. A population- based study . Scand J Gastroenterol 1997;32 
(10):1042-5.
Lindor KD, Kowdley  KV, Harrison ME, American College of G. ACG Clinical Guideline: 
Primary Sclerosing Cholangitis. Am J Gastroenterol 2015;110 (5):646-59; quiz 
60.
Molodeck y NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. I ncidence of 
primary sclerosing cholangitis: a sy stematic review and meta -analysis. 
Hepatology  2011;53 (5):1590-9.
Mudaliar S, Henry  RR, Sany al AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy  and 
safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 
diabetes and nonalcoholic fatt y liver disease. Gastroenterology 2013;145 (3):574 -
82 e1.
Murakami S, Takay ama F, Egashira T, Imao M, Mori A. Fermented papaya preparation halts the 
progression of non- alcoholic steatohepatitis in rats. Journal of Biophy sical 
Chemisty  2013;4 (2):84-90.
Nakamoto K, Takay ama F, Mankura M, Hidaka Y, Egashira T, Ogino T, et al. Beneficial Effects 
of Fermented Green Tea Extract in a Rat Model of Non- alcoholic Steatohepatitis. 
Journal of clinical biochemistry  and nutrition 2009;44 (3):239-46.
Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, et al. 6alpha -ethyl-
chenodeox ycholic acid (6-ECDCA), a potent and selective FXR agonist endowed 
with anticholestatic activity . J Med Chem 2002;45 (17):3569 -72.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page80 29 June 2016Saich R, Chapman R. Primary  sclerosing cholangitis, autoimmune hepatitis and overlap 
syndromes in inflammatory bowel disease. World J Gast roenterol 2008;14 
(3):331-7.
Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta- analysis: ursodeoxy cholic 
acid for primary  sclerosing cholangitis. Aliment Pharmacol Ther 2011;34 (8):901-
10.
GS-9674
Protocol GS -US-428-4025 Final 
Gilead Sciences, Inc. Original
CONFIDENTIAL Page81 29 June 201611. APPENDICES
Appendix 1.Investigator Signature Page
Appendix 2.Study Procedures Table for GS-US-428-4025
Appendix 3.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 4.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
GS-9674 
Protocol GS-US-428-4025 Final 
Gilead Sciences, Inc. Original 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404, 
U.S.A. 
STUDY ACKNOWLEDGEMENT 
A Phase 2, Randomiz..ed, Double-Blind, Placebo Controlled Study Evaluating the Safety, 
Tolerability, and Efficacy ofOS-9674 in Subjects with Primary Sclerosing Cholangitis Without 
Cirrhosis 
GS-US-428-4025 , Original, 29-June-2016 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
C. Stephen Djedjos (Printed) 
Medical Monitor 
Date PPD 
' Signature 
~STIGATORSTATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I wi U provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) Signature 
Date Site Number 
CONFIDENTIAL Page 82 29 June 20l6 
GS-9674
Protocol GS -US-428-4025 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page83 29June 2016Appendix 2. Study Procedures Table for GS-US-428-4025
Blinded Study Phase Treatment Weeks (±3 days)OLEWeeks 
(±5 days)
ScreeningaBaseline
(Day1)Week 1Week 2 Week 4 Week 8 Week 12 /ETbBlinded Study Phase 
follow-up visit c
(±5 days)OLE 
Baseline/Day 1, 
Weeks4,12, 24, 
36, 48, 60, 72, 84,  
96/ETbOLE 
follow-upd
Subject FastingeX X X X X X X
Written Informed 
Consentf X
Review 
Inclusion/Exclusion 
CriteriaX X
Medical History X
Partial Mayo Score X X X X X X X X X X
Pruritus VAS &5D -
Itchg X X X X X X X X X
QoL SF-36, PSC-
PRO & PBC-40g X X X X
Symptom -directed 
PEh X X X X X X X X X X
Vital SignsiX X X X X X X X X X
Heightand weightjX X X X X X X X X X
ChemistrykX X X X X X X X X X
HematologylX X X X X X X X X X
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
Screening• 
Coagulation Panel m X 
Cirrhosis X Assessments 
Lipid Profile 
C-Peptide, 
Hemoglobin A1C 
and Insulin 
Blood for X Biomarkers" 
Single PK and PD 
Sampling 
HIV-1, HBVand X HCV Serology 
Pregnancy T estP X 
Serum FSHq X 
fPD 
12-lead ECGs 
Fibroscan' 
CONFIDENTIAL Blinded Study Phase Treatment Weeks (±3 days) 
Baseline 
(Day 1) Week1 Week2 Week4 Week8 Week 12/ETb 
X X X X X X 
X X X X X 
X X 
X X X X 
xo X X X X X 
X X X X X 
I : I I I I I X 
X 
Page 84 Blinded Study Phase 
follow-up visit c 
(±5 days) 
X 
X 
X 
X Final 
Original 
OLE Weeks 
(±5 days) 
OLE 
Baseline/Day 1, 
Weeks 4, 12, 24, 
36, 48, 60, 72, 84, OLE 
96/ETb follow-upd 
X X 
X X 
X 
X X 
29 June 2016 J 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. 
Screening• 
Urine drug X screening1 
Urine collection 
(Biomarkerst 
Stool collection 
(Biomarkers )v 
IPPD 
Dispense GS-9674/ 
PTM GS-9674x 
Concomitant X Medications 
Adverse Events X 
Take GS-9674/ PTM 
GS-9674 TabletsY Baseline 
(Day 1) 
X 
X 
X 
X 
X Blinded Study Phase Treatment Weeks (±3 days) 
Week1 Week2 Week4 Week8 Week 12/ETb 
X X X 
X 
X X 
X X X X X 
X X X X X 
X-Daily (Baseline / Day 1 to Week 12) Blinded Study Phase 
follow-up visit c 
(±5 days) 
X 
X 
X 
X Final 
Original 
OLE Weeks 
(±5 days) 
OLE 
Baseline/Day 1, 
Weeks 4, 12, 24, 
36, 48, 60, 72, 84, OLE 
96/ETb follow-upd 
xx 
XY 
X 
X X 
X X 
X-Daily (OLE 
Baseline/ Day 1 
to Week 96) 
a The visit window may be extended under special circumstances with explicit approval of the Medical Monitor. Subjects who fail to meet eligibility criteria due to an abnormal 
laboratory result may undergo re-testing of the abnormal analyte during the screening window. This will be done at the discretion of the investigator and also with prior 
approval of the Medical Monitor. 
b Blinded Study Phase subjects discontinuing the study at any time for any reason (Early Termination- ET) should complete the procedures listed for the Week 12/ Visit AND 
the follow-up visit. OLE Phase subjects discontinuing the study at any time for any reason (Early Termination- ET) should complete the procedures listed for the Week 96/ 
Visit AND the follow-up visit if possible. 
CONFIDENTIAL Page 85 29 June 2016 I 
GS-9674 
Protocol GS-US-428-4025 
Gilead Sciences, Inc. Final 
Original 
c After completing 12 weeks of treatment in the Blinded Study Phase, subjects will return for the follow-up visit 4 weeks post the last dose of the study drug and at that time 
they can begin their OLE Phase. Follow-up visit for Blinded Study Phase and Baseline/Day 1 OLE visit can occur on the same day if convenient. If OLE Baseline/Day 1 and 
Blinded study follow-Up visit is on the same day subjects should only complete OLE Baseline /Day 1 assessments. 
d Follow-up visit should be completed during the Blinded Study Phase as well as the OLE Phase. 
e Subjects must be in a fasted state for at least 8 hours prior to blood collection. 
f Obtain written informed consent before initiation of any screening procedure. 
g QoL questionnaires and Pruritus assessments should be completed prior to any study procedures being performed and prior to the subject seeing a health care provider. Refer 
to the Study Reference Binder for guidance on QoL questionnaire administration. 
h Complete PE at screening and symptom-directed PE for other visits. The focus of a symptom-driven physical examination will be determined by the investigator based on 
subject complaint. 
Vital signs include blood pressure, heart rate, respiration rate, and body temperature. 
Height should be collected at Screening and Baseline/Day 1 only. Weight should be collected at all visits. Refer to the Study Reference Binder for specific instructions on 
how weight should be measured. 
k Blood chemistry will include: alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, alkaline phosphatase , bicarbonate, blood urea nitrogen (BUN), 
calcium, chloride, creatinine , glucose, lactate dehydrogenase (LDH), magnesium, phosphorus, potassium, sodium, total and direct bilirubin, total protein, uric acid, gamma­
glutamyl transferase (GGT). Also includes C-Peptide, insulin and hemoglobin A1C (HbA1c) for the Baseline/Day 1, and Week 12 visits. 
Hematology will include: complete blood cell count with differential (red blood cells, white blood cells, platelets, and hematocrit). 
m Coagulation Panel includes: PT, PTT, and INR. 
n Biomarker analyses include, but are not limited to, the tests listed in Section 6.12.1. Some of the blood collected for biomarkers may be stored for future testing. 
o PD sampling only at Baseline/Day 1. 
p Females of childbearing potential only (see Appendix 4). Serum pregnancy tests at Screening. Urine pregnancy test at all other visits, except Week 2 and 8. 
q OnlY..!!_quired for some female subjects- see AP£"'e• n.-di.,·x;..4.;.;. _______________________________ ---. 
rro -
s 1s not available at a site the test may be 
Drug screen for amphetamines, cocaine, and opiates (ie, heroin, morphine). 
u Urine Biomarker sample collection at OLE Baseline/Day 1, Weeks 24, 48, 72 and 96 only. 
v Stool sample collection only at OLE Baseline/Day 1, Week 48 and Week 96 visit. 
PD 
x Stuay aiUg Will be ass1gnea via ffie IWRS system every 4 weeks from Baseline/Day 1 through Week 8 in Blind Study Phase and OLE Baseline/Bay 1 and every 12 weeks 
thereafter in the OLE Phase. 
y Subjects to self-administer the study drug at the investigative site at the conclusion of the Baseline/Day 1 and Week 12 visit. 
CONFIDENTIAL Page 86 29 June 2016 
GS-9674
Protocol GS -US-428-4025 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page87 29 June 2016Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory 
Abnormalities
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_8.5x11.pdf
GS-9674
Protocol GS -US-428-4025 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page88 29 June 2016Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1.Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically documented ovarian failure.  
Women are considered to be in a postmenopausal state when they  are >
54years of age with 
cessation of pre viously occurring menses for > 12 months without an alternative cause.  In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
b.Definition of Male Fertility
For the purposes of th is study, a male born subject is considered of fertile after the initiation of 
puberty unless permanently  sterile by bilateral orchidectomy or medical documentation.
2.Contraception Requirements for Female Subjects
a. Study Drug Effects on Pregnancy and Hormonal Contraception
GS-9674 has not y et been studied in pregnant women. There are no preclinical data available to 
determine whether GS-9674 is teratogenic or fetotoxic in early humanpregnancy
. There are 
insufficient data to exclude the possibility  of a clinically  relevant interaction between GS -
9674 
and hormonal contraceptives that result in reduced contraception efficacy . 
Please refer to the latest version of the investigator’s brochure for additional information.
b.Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures. They must also not rely  on hormone -containing contraceptives as a form 
of birth control during the study . 
They must have a negative serum pregnancy  test at Screening 
and a negative urine pregnancy  test on the Baseline/Day  1 visit prior to randomization.  At 
minimum, a pregnancy  test will be performed at the end of relevant s ystem exposure.  I n the 
event of a d elayed menstrual period (over one month between menstruations), a pregnancy  test 
must be performed to rule out pregnancy .  This is even true for women of childbearing potential 
with infrequent or irregular periods. Female subjects must agree to one of the following from 
Screening until 30 day s following the lase dose of the study  drug GS-
9674.
GS-9674
Protocol GS -US-428-4025 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page89 29 June 2016Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifestyle. 
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Tubal sterilization
Essure micro- insert system (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 day s after the lase dose of the study  drug GS-9674.
3. Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must use condoms during treatment and for 90 day s after last 
dose of GS-9674. Additional contraception recommendations should also be considered if the 
female partner is not pregnant.
Male subjects must agree to avoid sperm donation from baseline throughout the study  period and 
for 90 day s after last dose of 
GS-9674.
4. Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation metho ds), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM).  Female condom and male condom should not 
be used together.
GS-9674
Protocol GS -US-428-4025 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page90 29 June 20165. Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study, or if they  become pregnant within 30 day s (90 days of partner of male subject) of last 
study drug dose. Subjects who become pregnant or who suspect that they  are pregnant during the 
study must report the information to the investigator and discontinue study drug immediatel y. 
Subjects whose partner has become pregnant or suspects she is pregnant during the stud y must 
report the information to the investigator.  Instructions for reporting pregnancy , partner 
pregnancy , and pregnancy  outcome are outlined in Section7.6.2.1.